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Abstract 
Background and Aims: 
Otitis media (OM) is a very common childhood disease with a significant 
burden for the child, the family and society. OM is defined as an inflammation 
or infection of the middle ear, always accompanied by effusion in the middle 
ear. The effusion prevents sound waves from entering the hearing organ in a 
normal way, thus OM is the most common reason for hearing impairment in 
children. OM is a spectrum of different phenotypes, the most common among 
children being acute otitis media (AOM), where the middle ear effusion (MEE) 
is accompanied by signs of acute infection (otalgia, fever, bulging or redness of 
the tympanic membrane). Most children have at least one episode of AOM 
before the age of two, but some develop recurrent AOM (RAOM). In chronic 
otitis media with effusion (COME) the MEE is prolonged without signs of acute 
infection and is usually highly viscous, creating an elevated degree of hearing 
impairment. OM is considered to be a complex genetic disease in which both 
genetic and environmental factor affect the risk. The genetic risk factor is most 
likely polygenic. Inherited genetic factors have been shown in several twin- and 
family studies to be strong risk factors for OM. Earlier genetic studies on OM 
have suggested variants in several candidate genes as risk factors for OM, but 
the results have not always been replicated in other populations. Hence, very 
little is known about the underlying genes that contribute to the genetic risk of 
this common childhood disease. Having better understanding of the genetic of 
OM would greatly contribute to our knowledge of the disease pathogenesis, 
leading to improvements in diagnosis, prevention, and treatment. 
The aim of the present study was to estimate the heritability of OM in the 
Finnish population in order to understand how much of the risk for OM is due 
to genetic variation. A second aim was to find genetic variations associated with 
OM in the Finnish population. 
Study design: 
The study was based on a Finnish family cohort with cases suffering from 
RAOM and COME.  
Subjects: 
Patients with RAOM and/or COME were recruited to the study when they had 
surgery due to OM at the Helsinki University Hospital’s (HUH) Department of 
Otorhinolaryngology, Head & Neck Surgery. Patients’ siblings and parents were 
also included as study subjects. Patient data was collected by questionnaires 
and DNA was extracted from blood samples. Altogether 3009 patients were 
recruited including 1573 children (701 were index patients and 872 were 
siblings), 711 fathers, and 725 mothers. Of the children 59% had RAOM, 43% 
COME, and 59% underwent insertion of tympanostomy tubes. A previous OM 
cohort with 217 Finnish study subjects was used as a replication cohort and was 
also included in the genome wide association (GWA) study. Two OM cohorts 
from the US (Pennsylvania and Oregon) and one from the UK (Oxford) served 
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as international replication cohorts. Functional studies were performed on 
study subjects from the index cohort.  
Methods: 
Heritability was estimated from the HUH cohort with the Solar software 
package, which utilizes a variance-component linkage method, especially 
designed to calculate heritability in pedigrees of different size and complexity. 
The first approach to assess genetic risk factors in our cohort was through a 
candidate gene study. Genotyping was performed on the Sequenom platform 
for 53 markers from 35 different genes that had previously been significantly 
associated (p < 0.05) with OM in other cohorts. The study was performed on 
624 unrelated study subjects, using 778 healthy blood donors as controls. The 
loci around the initial significant association (pcorr < 0.05) was followed up by 
genotyping (on the Sequenom platform) a subset of markers from the loci, by 
choosing 20 markers with linkage disequilibrium patterns to capture the whole 
loci (tagging gene approach). The downstream cytokine Tumor necrosis factor 
alpha (TNFα) of Toll-like receptor 4 (TLR4) was used for functional studies. 
TNFα protein expression was assessed in myeloid dendritic cells while mRNA 
expression was assessed in peripheral blood mononuclear cells on ten age- and 
sex-matched pairs with different genotypes.  
Replication analyses for the candidate gene study were done on a Finnish 
cohort (205 subject), a UK cohort (1269 trios), and two separate US cohorts 
(one with 403 families and another with 204 subjects).  
To find more genetic risk variants for OM, a GWA study was performed on 829 
Finnish study patients and, serving as controls 2118 previously genotyped, 
randomly selected subjects from the Finnish Health 2000 study, who 
originated from all parts of Finland. Significant associations were verified on 
other platforms (Sequenom and TaqMan). Replication analyses were 
performed on a UK family cohort with 4860 study subjects.   
Results: 
Heritability in the Finnish cohort was estimated to 39% (p = 7.3 x 10-9) for 
RAOM, 22% (p = 4.6 x 10-3) for COME, and 48% (p = 1.5 x 10-11) for any OM. 
One marker (rs5030717) in the TLR4 gene was significantly associated to OM 
(OR 1.33, p = 0.003) in the initial candidate gene study. In the tagging gene 
approach three markers (rs1329060, rs1329057, rs5030717), in strong linkage 
disequilibrium, were associated with OM (OR 1.34, pTCG = 0.003). The 
association was stronger in children with more severe phenotypes, a first AOM 
episode before the age of 6 months (OR 2.42, pbest = 0.00048) or those 
requiring multiple insertions of tympanostomy tubes (OR 1.65, 
pbest = 0.00004). The association was verified in the Finnish replication cohort 
for the three variants: rs1329060 (OR 1.37, p = 0.012), rs1329057 (OR 1.31, 
p = 0.027), and rs5030717 (OR 1.50, p = 0.05), but not in the international 
cohorts. TNFα expression in myeloid dendritic cells was lower in the study 
subjects with the TCG genotype compared to those with the alternative 
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genotype, whereas TNFα mRNA expression was higher in those with the risk 
TCG genotype compared to those with the alternative genotype. 
Assessing more than 300,000 genetic markers in 803 cases and 2073 controls 
revealed a locus on chromosome 19 associated with OM and one marker, 
rs16974263, proved to be genome-wide significant (p = 2.92 x 10-8) in 509 study 
subjects with COME. When genotyping the most significant variants in the UK 
cohort, an association was revealed for the opposite allele (rs16974263, 
OR 0.72, p = 3.21x10-4; rs4150992, OR 0.71, p = 1.62x10-4). 
Conclusions: 
All in all, we have shown that genetic predisposition strongly influences the risk 
of childhood OM in the Finnish population. Analysis of candidate genes 
disclosed that genetic variants of the TLR4 gene might influence this 
predisposition to OM. Children with the previously unrecognized risk 
haplotype in the TLR4 locus have a higher risk for RAOM, especially early onset 
RAOM. GWA study analysis revealed a novel risk locus on chromosome 19q, 
which is highly associated with COME in the Finnish population, but due to lack 
of replication of the same allele in a UK population, it is unclear what, if any, 
function the risk locus has on the pathogenesis of OM. 
Implications: 
OM is a common disease with genetic predisposition being a considerable risk 
factor. The particular genetic elements that confer the risk may be different in 
different populations, which may be due to differences in environments that 
can, potentially, give rise to heterogeneity in OM pathogenesis. Further genetic 
work on OM in different populations must be carried out to investigate the 
complex pathogenesis of the different phenotypes of OM and eventually 
improve diagnostics and treatment. 
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DZ Dizygotic (twins) 
eQTL Expression quantitative trait locus 
ET Eustachian tube 
FACS Fluorescence-activated cell sorting flow cytometry 
FBXO11 F-box only protein 1 
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mRNA Messenger ribonucleic acid 
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OR Odds ratio 
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T Thymine 
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Note All abbreviated genes are written in [italic], protein in [normal] font 
style throughout the document. 
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1. Introduction 
Childhood otitis media (OM) is a very common disease in children. Most children have at least one episode of 
acute otitis media (AOM) in their first years of life, and a large portion of those will experience recurrent AOM 
(RAOM) or chronic otitis media with effusion (COME). RAOM is associated with major adverse effects in the 
form of pain in children and days absent from work for parents. OM also negatively affects quality of life, for 
the child as well as the parents [1, 2]. COME is associated with hearing impairment and it may have an adverse 
influence on the development of cognitive skills as well [3, 4]. AOM is the most common reason for children to 
receive antibiotic treatment, and surgical treatment of OM is the most common reason for childhood 
anesthesia. These reasons account for the disease’s economic burden on society [5]. Taken together, OM causes 
significant burden and is a major factor impairing the health of young children.  
It seems that OM is a complex disease that comprises not only a few distinct phenotypes, such as AOM or 
COME, but a continuum of phenotypes [6]. As in the manner of other complex diseases, both host and 
environmental factors account for the risk. Environmental factors include daycare attendance, parental 
smoking, and lack of breastfeeding [7]. Twin and family studies have shown that heritability (h2) accounts for 
a substantial part of the risk for OM [8-10]. The hunt for genetic risk factors of OM has so far not been very 
successful, due to the high complexity of the genetic risk factors and also partly due to poorly designed studies. 
In theory, genetic studies of OM could help us to better understand the pathogenesis of OM which has been 
suspected to be partly due to the immaturity of the immune system, and partly due to the structural differences 
in the Eustachian tube of children compared to adults.  
The number of genetic studies of diseases has increased exponentially since the human genome was first 
sequenced in the year 2001 [11, 12]. Expectations for the new possibilities in the understanding of human 
physiology and pathophysiology were great. Genetic study techniques have evolved, become more available, 
are faster to perform, generate more genotyping data, and the cost for these techniques has also decreased. 
Numerous studies have been conducted but they have only been able to explain a small part of the genetic risk 
factor for complex diseases. The biological function of the verified risk variant has been explained in only a 
fraction of traits. Thus, disease diagnostics, prevention, and treatment have not changed as much as was 
expected in the beginning of the 21st century. 
Genetic studies to find risk variants for OM have included candidate gene studies, linkage studies, genome-
wide association (GWA) studies, and one sequencing study. Many genes involved in the innate immunity have 
been proposed as risk genes including surfactant, mannose-binding lectins (MBL), toll-like receptors (TLR), 
and cytokines such as tumor necrosis factor alpha (TNFα). GWA studies have suggested risk variants on 
chromosome 2, but the variants’ function in the pathogenesis of OM has not been studied in depth and is still 
unclear. Generally, the results from genetic studies of OM have not been replicable in other cohorts, which 
makes the results uncertain. Reasons for these inconsistent results are numerous: many of the studies have 
been underpowered, the phenotype investigated has varied between cohorts, and the risk factors vary between 
populations.  
This thesis aims to bring new insights regarding the genetic risk in OM. To overcome the drawbacks of previous 
studies, we used a large, clinically well-defined family cohort where RAOM and/or COME exists, with stringent 
definitions for the phenotypes studied. To ensure a genetic risk component exists in our cohort, and in the 
Finnish population, we chose to start by estimating the heritability, to verify that the risk for childhood OM is 
actually heritable in the Finnish population. The quest for genetic risk variants of OM in the Finnish population 
is carried out utilizing state-of-the-art genetic techniques. We also aim to test if the genetic risk factors for OM 
in Finland are the same in other populations, and to investigate the biological function of the proposed genetic 
risk variants in the Finnish population. We hope that the studies will shed light on the complex risk factors and 
pathogenesis for childhood OM, and thus help to prevent and treat this common and burdensome disease 
spectrum. 
Review of the Literature 
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2. Review of the Literature 
2.1. Otitis media 
OM is defined as inflammation in the middle ear. Anatomically, the healthy middle ear is an air-filled space 
connected to the nasopharynx by the Eustachian tube (Figure 1). The middle ear contains the ossicles of the 
hearing organ which transmit sound waves from the outer ear into the actual hearing organ (the cochlea) in 
the inner ear. AOM is a complication of an upper respiratory tract infection (URI) whereby purulent effusion 
pools up in the middle ear, causing pain due to pressure on the tympanic membrane. Typically, AOM resolves 
spontaneously or with antibiotic treatment in days/weeks, but about 15% of AOM cases give rise to indolent 
COME. COME is defined as prolonged (> 2-3 months) middle ear effusion (MEE) that can be either serous or 
mucous. About 16% of COME diagnoses appear without a known history of AOM [13]. AOM can also give rise 
to chronic suppurative OM (CSOM) with tympanic membrane perforation and chronic discharge of the ear. 
 
Figure 1 The healthy middle ear is an air-filled space connected to the nasopharynx by the Eustachian tube. Sound waves 
travel through the external acoustic meatus, are amplified by the tympanic membrane and ossicles, and lead to the cochlea, 
which is the actual hearing organ. To perceive the sound, the signal travels via the cochlear part of the vestibulocochlear 
nerve to the central nervous system. (Illustrator: Helena Schmidt) 
2.1.1 Epidemiology 
Childhood OM includes AOM, COME, and CSOM, although these phenotypes actually exist along a continuum 
of the disease [6]. The incidence of childhood OM varies with age and across different populations. The 
incidence of AOM is highest among children ages 1-4 years, globally occurring in about 61% of children this 
age. The incidence in all age groups varies across populations, from 3.6% in Central Europe to 43% in Sub-
Saharan Central Africa. The incidence of CSOM is higher in developing countries and is highest among children 
< 12 months (global incidence 15%) [14]. The prevalence of COME is estimated to be 4.4%. Some children 
experience recurrent episodes of AOM (RAOM); by the age of two, 4% of children have had four or more AOMs, 
with the incidence of RAOM decreasing with age [15]. In recent years, there has been some indication of a 
decrease in the incidence of childhood OM; explanations for this might be the introduction of the 
pneumococcal conjugate and/or the influenza vaccination, an increase in breastfeeding, a reduction in parental 
smoking, and more stringent diagnostic criteria [16, 17]. 
2.1.2 Risk factors and prevention 
Risk factors for OM have been extensively studied. They can be either host risk factors, or environmental 
factors. Young age, family history, day-care attendance and upper respiratory infections are the leading risk 
factors for OM (Table 1). 
 Review of the Literature 
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Table 1 Risk factors for OM [7, 18-23] 
Host factors Risk probability1 Level of evidence2 
Allergy  +/- II 
Allergic rhinitis + III 
Craniofacial abnormality + IV 
Gastro esophageal reflux + IV 
Adenoid + V 
Male sex + II 
Family history of OM ++ II 
Young age +++ III 
Environmental factors   
URI +++ II 
Day-care attendance +++ II 
Season + III 
Family size +/- II 
Passive smoking + II 
No breastfeeding + II 
Use of pacifier ++ II 
1 +/- = unlikely, + = probable risk factor, ++ = risk factor, +++ = important risk factor. The risk probability is based on the number of 
studies showing association versus studies not showing association for the risk factor.  
2 I = randomized controlled trials, II = well delineated cohorts, meta-analyses of cohorts or large case-control cohorts, III = less 
discriminatory power than clinical trials and prospective cohorts (case-controls of prevalent cases), IV = cross-sectional studies, 
observational studies, V = recommendations from medical guidelines or specialist opinion 
A parent who smokes may exhale harmful substances during normal breathing, immediately after smoking, 
thereby exposing the child even if the smoke itself is not in the vicinity of the child. It has also been suggested 
that since the nasopharyngeal colonization is different among smoking parents and their children, compared 
to non-smokers and their children, this affects how susceptible they are to OM [24].  
Cochrane is a global independent network of researchers that work together to produce credible health 
information, without commercial, or other, conflicts of interest (www.cochrane.org). They produce, among 
other things, comprehensive reviews regarding diagnostics and treatment based on previous studies. There are 
several Cochrane reviews regarding the treatment and prevention of OM: 
Pneumococcal vaccination has a slight beneficial effect on reducing AOM in healthy children who 
otherwise have a low risk for OM (relative risk reduction 7%, 95% CI 4% - 9%) [25]. Influenza 
vaccination also seems to reduce the number of AOMs (RR 0.80, 95% CI 0.67 - 0.96) as well as the use 
of antibiotics (RR 0.70, 95% CI 0.59 - 0.83) [26]. Additionally, healthy children regularly using xylitol 
have a reduced risk of occurrence of AOM (RR 0.75; 95% CI 0.65 - 0.88) [27]. There is inconclusive 
evidence regarding the intake of zinc supplements in reducing the number of AOM episodes [28]. 
Probiotics reduce the number of URIs (OR 0.53; 95% CI 0.36 = 0.80, p = 0.002), the duration of the 
URI episode (mean difference -1.89; 95% CI -2.03  to -1.75, p < 0.001), the school absences due to URI 
(OR 0.10; 95% CI 0.02 - 0.47), as well as reduce the use of antibiotics during the URI compared to 
placebo (OR 0.65; 95% CI 0.45 - 0.94) [29]. Since AOM is usually preceded by a URI, it could be 
extrapolated that probiotics could reduce AOM, but so far the results for reducing OM with probiotics 
are few and inconclusive [30, 31].  
Taken together, there is good evidence that the ways to reduce childhood OM are to: have non-smoking 
parents, breastfeed children, delay daycare attendance, vaccinate children, and regularly use xylitol products. 
2.1.3 Pathogenesis 
The pathogenesis of OM is multifactorial, with the infection, anatomic factors, host factors, and immature 
immune system all having their role. AOM is usually preceded by a viral URI, the most common being 
respiratory syncytial virus (RSV), adenovirus, rhinovirus (RV), coronavirus, influenza and parainfluenza virus, 
as well as enterovirus and the more newly discovered human metapneumoviruses and human bocavirus [32]. 
It is suggested that the viral load changes the structure and immune response of the mucous membrane in the 
nasopharynx, Eustachian tube and middle ear [33, 34]. The three most common bacterial strains causing AOM 
are Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus pneumoniae. Streptococcus pyogenes 
accounts for only about 1-5% of AOM [35]. The microbiology in CSOM is quite distinct, however, with 
Staphylococcus aureus, Pseudomonas aeruginosa, Proteus vulgaris and Klebsiella pneumoniae being the 
most common [36]. 
The Eustachian tube (ET) has an important role in maintaining the homeostasis in the middle ear; it functions 
as a ventilator for the middle ear, protects the middle ear from external irritants, and drains the middle ear 
[33]. Impaired functioning of the ET leads to MEE, as seen in children with cleft palate who almost always 
develop COME before correctional surgery [37]. In children, the ET is shorter, has a different angle, and the 
Review of the Literature 
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cartilage is softer than in adults, which may predispose children to OM. Obstruction by an enlarged adenoid 
can also cause impairment of ET function and predispose one to OM. [33]  
The immunological defense in the middle ear acts thorough both innate and adaptive immunity. The innate 
immunity comprises the mucus containing several anti-microbial substances, as well as epithelial cells and 
other cell types with the various receptors of innate immunity. The adaptive immunity against OM includes 
the formation of secreted and extracellular antibodies that stop bacterial adhesion and clears the pathogens 
through opsonization and phagocytosis. Dendritic cells (DC) of the mucous epithelium and mucosal-associated 
lymphoid tissues, including the adenoids and palatine tonsils, initiate the cascade of adaptive immunity. [34] 
2.1.4 Diagnosis and treatment 
The symptoms of AOM include otalgia, fever, irritability of the child, tugging on the ear, and otorrhea. The 
clinical diagnosis is based on otoscopy, or otomicroscopy, of the ear. For the diagnosis of AOM, MEE must be 
present with erythema or a bulging of the tympanic membrane, or otorrhea without otitis externa [38-40]. The 
diagnosis of COME is based on the detection of MEE for  >2-3 months [39]. Tympanometry is a useful tool in 
the diagnosis of both AOM and COME. [41] 
Most AOMs heal spontaneously without complications, in a large meta-analysis of over 3000 children with 
AOM, only seven cases of severe complications (mastoiditis, meningitis, pneumonia, transient facial nerve 
paralysis) were found [42]. The same meta-analyses revealed that the use of antibiotics have a clear positive 
effect on pain reduction in AOM [42]. The differences in tympanic perforation and tympanometry findings 
during follow-up are only modest between patients with antibiotic treatment compared to placebo. The 
possible adverse effects of antibiotics (vomiting, diarrhea, rash, allergic reactions) (number needed to treat to 
harm (NNTH) = 9) should be taken into consideration when deciding on the therapy for AOM. In a meta-study 
of children under age two with bilateral AOM, fewer had pain and/or fever in the antibiotics group compared 
to the group that received placebo (risk reduction 25%, 95% CI 14% - 36%). In children older than two years, 
the risk reduction was only 12% (95% CI -1% - 25%). Among children with otorrhea, those in the antibiotics 
group had less fever and/or pain compared to controls (risk reduction 36%, 95% CI 19% - 53%). In subjects 
with AOM without otorrhea, the risk reduction was 14% (95% CI 5% - 23%) [43]. This implies that antibiotics 
are most useful in children under the age of two with bilateral AOM, or those with otorrhea accompanying 
AOM. [42] The first choice of antibiotics is amoxicillin, which can be administered once or twice daily. When 
administration of amoxicillin once or twice daily was compared to administration 3-4 times a day in a pooled 
analysis of 1601 children with AOM, there was no measureable difference between the groups: achieving a 
clinical cure at the end of therapy (RR 1.03 , 95% CI 0.99 - 1.07), during therapy (RR 1.06, 95% CI 0.85 - 1.33), 
or at follow-up (RR 1.02, 95% CI 0.95 - 1.09), experiencing RAOM (RR 1.21, 95% CI 0.52 - 2.81); complying 
with medication instruction (RR 1.04, 95% CI 0.98 - 1.10), and overall experiencing of adverse events (RR 0.92, 
95% CI 0.52 - 1.63) [40, 44]. It is also important for the pain that often accompanies AOM to be managed 
adequately [40]. 
Surgical treatment of childhood OM includes insertion of tympanostomy tubes and/or adenoidectomy. 
Paracentesis (incision of the tympanic membrane) with insertion of tympanostomy tubes is performed for the 
draining of prolonged MEE, and also to reduce the number of AOM episodes among RAOM cases. The effect 
of tympanostomy tubes in the treatment of RAOM is mild [45], but it increases diagnostic accuracy and 
decreases pain in subsequent AOMs. The object of adenoidectomy is to improve the function of the ET by 
removing an obstructive adenoid. In some cases, the adenoid’s colonization of bacteria is the source for 
recurrent bacterial AOMs [46]. A large analysis of pooled data including 71,353 children concluded that there 
was a reduced need for re-tympanostomy among those that had an adenoidectomy accompanying the initial 
tympanostomy tube insertion, compared to those with primary tympanostomy tubes alone (17.2% vs 31.8%) 
[47]. This effect was smaller in children younger than 4 years. Similar results were acquired for another meta-
analysis of 10 randomized controlled trials with children up to 12 years of age diagnosed with RAOM and/or 
COME in which adenoidectomy (with or without tympanostomy tubes) was compared with non-surgical 
treatment or grommets alone. Children < 2 years with recurrent AOM seemed to benefit from adenoidectomy 
(number needed to treat (NNT) = 9), as well as children aged ≥ 4 years with COME (NNT = 6). [48]  
Tympanostomy tube insertions in children with COME improve hearing by 10-12 dB in the first six months 
after the procedure, compared to controls, but the difference decreases after six months due to the natural 
resolution of COME in untreated children. The tubes do not seem to affect language development, behavior or 
quality of life. [49]  
According to a Cochrane review of 12 randomized control studies with 945 participants, no evidence was found 
to support the use of intranasal steroids for improving the resolution of COME [50]. Oral steroids with (RR 
4.48, 95% CI 1.52-13.23) or without antibiotics (RR 1.99, 95% CI 1.14-3.49) seem to resolve COME faster during 
the first month, but no long-term benefits on resolution and no advantage on hearing can be shown [50]. With 
the apparent adverse effect of both oral steroids and antibiotics, their use in the therapy of COME should be 
discouraged. The use of antihistamines and decongestants are also not recommended, as they have no benefits 
in the treatment of COME, on the contrary, have adverse effects (NNTH=9) [51]. 
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2.1.5 Complications 
The most common complication of OM is tympanic membrane perforation, which is more common when the 
pathogen is Streptococcus pyogenes. It usually heals spontaneously once the otorrhea ends [52].  
MEE accompanying OM is the most common reason for acquired hearing loss in children worldwide [53]. 
Hearing loss can also be induced by OM affecting the inner ear’s hearing cells [54] or CSOM with or without 
cholesteatoma changing the anatomy of the middle ear. The prevalence of hearing impairment caused by OM 
is 3.1% globally, with the incidence rising with age and being higher in developing countries [14]. This hearing 
impairment has been connected to delays in language development and impaired social behavior. [55] 
The hazardous complications of OM include extracranial problems, such as facial nerve palsy, labyrinthitis (i.e. 
vertigo and sensorineural hearing loss), mastoiditis, and petrositis, as well as intracranial problems, such as 
brain abscess, meningitis, epidural abscess, encephalitis, cerebellitis, subdural abscess, sinus cavernosus 
thrombosis, and lateral sinus thrombosis [14, 56]. The annual mortality incidence from OM complications is 
3.3 cases per million, with the highest incidence in children under the age of 5 and in the elderly (> 75 years 
old). Mortality is higher in the developing world [14]. In developed populations, severe complications of AOM 
are rare and their incidence seems to be the same in children who are treated with antibiotics compared to 
placebo [42]. 
2.2. Genetic studies on complex diseases 
Since sequencing of the first human genome was accomplished in 2001 [11], the number of genetic studies on 
human diseases and traits has grown exponentially. Techniques for genetic studies have developed at an 
increasing speed and become more affordable and available. Numerous genomic databases, such as the 
HapMap project [57], have been created as tools for the study of both rare and especially complex genetic 
disorders (CGD). CGDs are phenotypes that arise through the interaction of several factors, both genetic 
variants and environmental factors [58]. Most CGDs have a heritability of 30-60%, but it has been challenging 
to find the genetic variants accounting for the heritability. High expectations to explain the genetic risk for 
CGDs accompanied the introduction of the genome wide association (GWA) technique. Unfortunately, 
typically low risk (OR < 1.5) variants have been detected that only explain part of the heritability of CGDs, thus 
giving rise to the question of the “missing heritability” [59]. Methods to explain all of the heritability are still 
evolving. Studies on rare genetic variants, gene-gene (epistasis) interaction, environmental interaction with 
genes, and variants external to the protein-coding genome, are ways to increase the understanding of CGDs. 
Also, studies on non-coding, regulatory variants that affect transcribed parts of the genome might extend our 
knowledge of CGDs. Most CGDs are polygenic, comprising numerous low risk common variants, as well as rare 
variants. There is also large genetic heterogeneity between individuals with the same phenotype, as different 
sets of genetic risk alleles can produce the same phenotype.[60]  
2.2.1 The human genome 
The structure of DNA 
The human genome consists of DNA (deoxyribonucleic acid) that is packed in the cell’s nucleus on 23 pairs of 
chromosomes (22 pairs of autosomes and two sex chromosomes) and, additionally, there is mitochondrial 
DNA (mtDNA) [61]. The autosomal chromosomes are annotated 1-22, and the sex chromosomes as X and Y. 
DNA is a complex molecule built as a strand from four kinds of nucleotides. The nucleotides comprise three 
parts: a nitrogenous base, deoxyribose, and a phosphate group. The nitrogenous base is different in the four 
nucleotides: adenine (A), thymine (T), guanine (G), and cytosine (C). The nitrogenous base is attached to the 
5’ position of the deoxyribose carbon ring and a free hydroxyl (OH-) group is attached to the 3’ position of the 
same ring, thus the annotation of the 5’ and 3’ end of the DNA strand. In a DNA strand, the 5’ of one nucleotide 
is attached to the 3’ of the next nucleotide. The stable DNA strand appears as a mirrored double-strand, where 
the nucleotide A is attached to a T, and C to G through a hydrogen bond, with one strand running in the 3’-5’ 
direction and the other in the 5’-3’ direction. DNA is packed in the nucleus of cells as a double-stranded helix, 
coiled around histone proteins (the chromatin). When a cell divides in the mitosis phase of the cell-cycle, DNA 
is copied through the process of replication into the new cells. Gametes (ovums and sperms) contain one sex 
chromosome and 23 autosomal chromosomes and are produced during the process of meiosis. 
A gene, or a genetic locus, can have different forms, called alleles. Humans have two alleles at each genetic 
locus that are inherited randomly from each parent, with the exception that mtDNA is always inherited from 
the mother and the Y chromosome from the father. The allele pair is denoted as the genotype for that gene or 
genetic variant. A heterozygotic genotype consists of two different alleles, whereas a homozygotic genotype is 
made up of two identical alleles. Hardy–Weinberg equilibrium (HWE) refers to genotype frequencies that are 
constant in large, randomly mating populations if no evolutionary influences are present. In that case, if the 
frequency of one allele A is p and the frequency of the alternative allele a is q, where p+q=1, then in the next 
generation the frequencies for the genotype AA is p2, Aa is 2pq, and aa is q2, where p2+2pq+q2=1. Deviation 
from HWE is calculated in association studies using the observed genotype frequency and comparing it with 
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the expected genotype frequency according to HWE. A deviation in controls can be due to population 
stratification, or genotyping error [62]. 
Transcription and translation 
The genome contains about three billion base pairs, of which only 1.1% is protein encoding, or about 20,500 
coding genes. A coding gene is a locus of DNA that codes for proteins by the process of transcription and 
translation. The gene contains the transcribed sequence, the exon, which is only a small part of the gene, as 
well as introns, promoters, and enhancers or silencers. In transcription, the DNA of a gene is used as a template 
to build RNA (ribonucleic acid). The promoter is in the 5’ end of the gene where the transcription starts by the 
binding of transcription factors and RNA polymerase. The produced RNA can be non-coding, the function of 
which is somewhat unclear to date, or protein coding mRNA (messenger RNA). There is evidence suggesting 
the transcription of > 50,000 non-coding RNAs in the genome [63]. Regulatory sites of the genes are upstream 
or downstream from the coding DNA, enhancers increase transcription when binding to transcription factors, 
whereas silencers decrease transcription by inactivating RNA polymerase. The RNA strand is also composed 
of four different nucleotides. The nucleotides of RNA have a ribose unit, a phosphate group, and a nitrogenous 
base of A, C, G, or U (uracil). RNA is single stranded and transcribed from the 5’UTR (untranslated region) to 
the 3’UTR by the pairing of nucleotides from the template DNA strand (A-U, T-A, G-C, C-G). After 
transcription, non-coding parts, introns, are removed by splicing. In the process of translation, the coding 
mRNA is used as a template for the amino-acid chain of a protein. Three nucleotides in the mRNA strand 
comprise a codon that is translated into one of 20 different amino acids or which indicates translation to be 
stopped [61]. The genome encodes all the instructions for the fertilized egg to become a human that can 
respond to environmental factors, and to reproduce. Almost all the cells of a human contain the same genetic 
information, but the different cell types can alter their gene expression to create all the features of the human. 
Genetic variation 
The genes can, by alternative splicing of mRNA and through duplicate promoters in the gene, produce more 
proteins than the number of genes [64]. Up to 99.9% of the DNA between individuals is identical. Genetic 
variation between individuals has evolved through mutation, and reproduction. Mutations produce permanent 
changes in DNA that can be anything from small one base DNA changes, up to large structural changes. They 
can develop when damaged DNA is repaired with errors, or due to error in replication. Variations in the 
genome can appear as, for example, insertions, deletions, copy number variations (CNV), duplications, 
inversions, translocations, and microsatellites [65]. The most common variants are the single nucleotide 
polymorphisms (SNPs, also called single nucleotide variants (SNV)), a change of one nucleotide to another. 
There are about 10 million SNPs with minor allele frequency (MAF) > 0.05. Most of the SNPs are neutral, only 
about 2% affect structural changes in protein through amino acid substitution, frameshift, termination, or 
protein translation [63]. SNPs can be identified by a reference SNP ID number (rs number) [66]. Variants of 
SNPs in non-coding regions can be functional, e.g. by altering splicing signals and mRNA stability. Also, SNPs 
in promoter regions can appear functional by affecting transcription factor binding sites, enhancers, and 
silencers. In the process of human reproduction, great genetic variation is achieved. First, during meiosis, the 
23 different chromosome pairs can divide randomly. Secondly, recombination occurs during meiosis when 
maternal and paternal DNA are crossed over between homologous (the same number) chromosomes. Finally, 
fertilization of the maternal and paternal gametes is random. 
Evolutionary factors that impact the allele frequencies in populations are migration, selection, and genetic 
drift, these have caused population stratification (differences in allele frequencies between subpopulations). 
Haplotype 
Adjacent genes and genetic variants tend to be inherited together, if recombination does not take place during 
meiosis. Sequences of alleles that are inherited together (co-segregated) are called haplotypes. Genes or 
variants that appear more often together than would be expected by chance are said to be in linkage 
disequilibrium (LD). The recombination history in a population is reflected by the presence of LD between 
alleles, and the LD pattern can vary both between and within populations. This variation is accounted for by 
several population genetic factors, including migration, population admixture, and genetic drift. Haplotypes 
in isolated populations with low genetic diversity, or recent mutations in a population, are more likely to show 
vast LD that can also extend over long distances in the genome [67]. The International HapMap Project 
developed a haplotype map of the human genome to describe the common patterns of variation in sequences 
of DNA [57]. This was done by characterizing SNPs, their frequencies, and the correlations between the SNPs 
in DNA samples from individuals in populations of African, Asian, and European ancestry. 
The knowledge of LD among variants is used in GWA studies by choosing SNPs (tagging SNP) that capture the 
genotype information in a haplotype block, instead of genotyping all SNPs in the block. The coefficient for LD 
is usually expressed as a coefficient of linkage disequilibrium │D’│ or as the correlation coefficient r2, where 
there is no correlation if │D’│ = 0, or r2 = 0. The closer that │D’│ or r2 is to 1, the better the marker’s genotype 
correlates to the other variant [68]. 
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2.2.2 Linkage studies 
Linkage studies are a tool to find genomic loci that affect the susceptibility to a trait. The regions are found by 
genotyping markers for individuals in pedigrees with several affected individuals and testing for co-segregation 
of chromosomal regions with the trait of interest. Segregation patterns of genetic markers that are similar to 
the pattern of the studied trait are likely in the region of the causative genetic loci. Traditional linkage analyses 
are either parametric or non-parametric (NPL). In parametric linkage analysis, a specific linkage model is 
tested and used for phenotypes with a known pattern of inheritance and a logarithm of odds (LOD) score is 
produced. The LOD score describes the strength of the linkage results, the higher the value the greater the 
likelihood of linkage. In NPL analysis, it is tested if there is deviation in the sharing of loci compared to the 
inheritance that would be expected by chance. NPL is best applied to phenotypes where the pattern of 
inheritance is not known, for instance, in the analysis of CGDs, where no single or simple model describes the 
mode of inheritance [69]. The design of traditional linkage studies enables them to identify high risk loci for 
the studied trait and, therefore, are best suited for monogenetic diseases. Whereas, in complex traits, the power 
of linkage analysis to identify common variants with modest effects is limited [70]. 
2.2.3 Association analysis  
In association analysis, the frequency of an allele or a genotype is compared between affected individuals and 
control subjects. If the studied allele is more common in the affected population, it is suspected to be a genetic 
risk variant or a proxy of the risk variant which is in LD with the actual risk variant. Association analyses can 
be candidate gene studies or hypothesis-free GWA studies [71]. The control subjects should be from the same 
population as the affected individuals, in order to control for population stratification. The control subjects can 
either be unselected (trait status is unknown) or negative for the trait of interest. The transmission 
disequilibrium test (TDT) is used in family-based genetic association studies to control for population 
stratification [70]. In a TDT test, the genotypes for parents and affected children are assessed and the frequency 
of transmission of an allele from a heterozygous parent to affected children is measured. 
Candidate gene studies 
One approach to understanding the genetic basis of traits are candidate gene studies; these rely on a hypothesis 
about the risk gene, namely, that it is involved in the pathogenesis of the trait of interest. Most candidate gene 
studies have been performed on SNPs; commonly used techniques are, for instance, TaqMan [71] or KASP [72] 
which genotype SNPs one by one, or Sequenom, which allows genotyping several SNPs in parallel [73]. When 
taking into account the LD between markers, a tagging gene approach can be used to capture large segments 
of a loci by genotyping only a few SNPs [74]. The candidate gene approach, however, involves several 
challenges in explaining the genetic risk. First, it relies on a hypothesis of an allele being risk for a trait, or in 
LD with the actual risk variant, thus marker selection is crucial. Secondly, CGDs are mostly polygenic with 
individual variants usually only having a small effect on the trait. There is also a vast genetic heterogeneity 
among the traits, with different variants or sets of variants being responsible for the same trait. Control 
selection is vital in order to control for the different LD patterns among populations and other hidden 
confounding effects. To decrease the risk of false-positive findings, studies should have large cohorts, use 
correction for multiple testing, and replicate the findings in another cohorts. Large cohorts are needed to give 
the studies enough power to detect significant association. Correction for multiple testing should be used if 
several genetic variants or traits are investigated in one study. It is also nearly impossible to take into account 
all the environmental factors affecting the trait [67]. 
GWA studies 
In GWA studies, up to several millions of SNPs are studied on microarrays for large samples of cases and 
controls. The GWA study is designed to find association of a trait with common variants (MAF > 5%) of low 
effects (OR < 1.5), but it is not sensitive enough to find rare variants. By taking into account the LD of SNPs, 
most of the common variants in the genome can be studied using 0.5-1 million tagging SNPs. Thus, it is a 
hypothesis-free method, without any assumptions about risk variants, rather, SNPs can be scanned along the 
whole genome. The results are usually visualized along the genome as Manhattan plots, with the genomic 
position of markers on the x-axis and their associated -log10(p value) value on the y-axis. 
The first GWA study was published in 2006 on a small cohort of 96 patients with age-related macular 
degeneration and 130 healthy controls. The study of almost 100,000 SNPs found one intergenic marker on 
chromosome 10q26 that was associated with age-related macular degeneration (OR = 11.1, p = 4.1x10–12, 95% 
CI 4.83-25.69) [75]. The first large GWA studies for CGDs were published in 2007. One of them was a UK 
(United Kingdom) study targeting seven complex human diseases: type 1 and type 2 diabetes, coronary artery 
disease, hypertension, Crohn's disease, rheumatoid arthritis, and bipolar disorder; 2,000 cases for each trait 
and 3,000 shared controls were genotyped for about half a million SNPs [76]. In that study, 15 associated SNPs 
with p < 5x10-8 were discovered.  
Review of the Literature 
 20 
Following the pioneer analyses, GWA studies have become a common method for studying genetic association 
in CGDs. Previously, many candidate gene studies were underpowered due to small sample size, nor was 
correction for multiple testing undertaken, leading to false-positive results. Furthermore, replication of the 
results were rarely performed. This led to criteria for a true association in a GWA study being set at the p 
value < 5x10-8 and the association must be replicated in a separate sample of cases and controls [70, 77, 78].  
The biological function of the positive association in a GWA study is not always self-explanatory. The variant 
might not be the risk-conferring marker, but be tagging the actual functional variant. Many of the positive 
genetic association lies in the introns or intergenic regions. The associated variants are usually not directly 
altering the protein sequence in translation (coding SNP), but are variants that affect transcription (both 
coding and non-coding RNA) (regulatory SNP), or RNA function and processing (structural SNP) [60].  
Epistasis (non-additive gene-gene interaction) is acknowledged as an important regulator of genes, but is still 
largely unresearched in GWA studies. Most CGDs are also polygenic, with several genetic variants adding to 
the genetic risk. Therefore, the leap from the positive genetic association to understanding the function on a 
molecular level, and further on to invent new treatments has been lagging. 
2.2.4 Sequencing  
Genetic sequencing refers to a method where all the nucleotides of a DNA sequence are characterized. Sanger 
sequencing [79] was introduced back in 1977 and can be applied when studying < 1000 nucleotides. The 
sequencing requires the DNA template to be studied, a DNA primer and, both unlabeled and labeled 
nucleotides that elongate the DNA primer in a PCR (polymerase chain reaction), according to the DNA 
template. The labeled nucleotides also terminate the elongation of the strand. The elongated strands are 
organized by size and the labeled nucleotide can be read by a detector. The sequencing of the whole genome or 
the exome is referred to as Next Generation Sequencing (NGS). These methods are able to sequence billions of 
nucleotides. They were introduced in 2008 [80] and the studies have since increased rapidly. They enable 
researchers to find rare variants, which remains their main function, but they have also been used for CGDs. A 
challenge for genome-wide sequencing studies is statistical power; very large cohorts are needed in order to 
find significant association for rare variants. The drawbacks of this sensitive method are the high expense and 
the challenge of the large amount of data, from the perspective of storage, handling, and analysis. The impact 
of these drawbacks will probably diminish in the future, though, since computer capacity will continue to grow 
and the cost of genotyping will continue to decrease [81, 82].  
2.2.5 In silico analysis  
To assist in the study of genetic risk factors, many on-line, open source databases have been developed. OMIM 
(Online Mendelian Inheritance in Man), the database on human genes and genetic phenotypes, was 
established freely on-line as early as 1987 (omim.org/about). It is a reference database that covers all 
genetically inherited disorders, and over 15,000 genes. Through the HapMap project (see section 2.2), millions 
of SNPs were discovered and many studies have used the data in candidate gene and GWA studies. The project 
was discontinued in June 2016 and the 1000 Genome project aimed at further characterizing genomic 
variation by systematically targeting more rare variants than the HapMap project. The 1000 Genome project 
(www.1000genomes.org) has, through sequencing, recorded genetic variants in 26 different populations in 
Africa, the Americas, Europe, and Asia. These variants include all SNPs with frequencies > 1%, variants with 
frequencies < 1% in functional gene regions, and structural variants such as CNVs, insertions, deletions, and 
inversions. The database also contains information about haplotype structures in the various populations [83]. 
The ENCODE (Encyclopedia of DNA Elements) project (https://www.encodeproject.org) was established to 
assess the functional sequences in the human genome (as well as the mouse, fly, and worm). It has been carried 
out on 300 different cell and tissue types. The functional elements include chromatin structure, DNA 
methylation, 3D genome interaction, DNA-protein interaction, transcription, gene expression, and RNA-
protein interaction. This information can be used to study the function of a genetically associated loci or to find 
the causal genetic variant and in that way reveal the molecular genetic mechanism for a trait [84]. 
The FANTOM (Functional Annotation of the Mammalian Genome) consortium has created the FANTOM5 
databases for transcriptional expression in different cell types across the human body (and mice) to get a 
comprehensive view of gene expression in the body (fantom.gsc.riken.jp/5). The information in the database 
includes identified transcription start sites (TSS) and their usage in cells, cell-lines, and tissues (~1800 
different cell, cell-lines, and tissues for humans [85]) that are collected from single-molecule sequencing of 
mRNA [86]. 
The GTEx (Genotype-Tissue Expression) portal (www.gtextportal.org) provides information on genetic 
variants that show eQTLs (expression quantitative trait loci). eQTLs are genomic variants that contribute to 
high variation in expression levels of mRNA. The database has been collected by studying gene expression in 
different tissues and cells and the expression levels are compared to the donor’s genotype [87]. 
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The Human Protein Atlas (www.proteinatlas.org) is a database with protein expression information for the 
majority of the human protein-coding genes in different types of normal human tissues, different cancer types, 
and different human cell lines [88]. 
The GRASP (Genome-Wide Repository of Associations Between SNPs and Phenotypes) portal 
(https://grasp.nhlbi.nih.gov) contains data on all genetic associations (p < 0.05) from published GWA studies 
that comply with the stringent criteria for GWA studies and are performed on > 25,000 markers [89]. 
In so-called in silico analyses, data from these databases are integrated with genotyping results to assist in the 
further analysis of genetic association and in order to understand the clinical meaning of the findings [82, 90]. 
2.3. Human genetic studies on OM 
An important risk factor for OM is a family history of the condition, which suggests that genetic factors 
influence the risk for developing OM [19]. Several studies have proven that OM has a heritable component, 
and numerous studies have attempted to assess the genetic markers that are associated with OM. The hunt for 
genetic markers have been carried out through various candidate gene studies, two linkage studies, two GWA 
studies, and one sequencing study. A compilation of positive association results are presented in Figure 2 and 
Table 2. Most of the studies have been performed on mainly Caucasian populations, so generalization to all 
populations is not necessarily possible. Several animal studies on OM have been conducted, many thoroughly 
performed, using state-of-the art techniques [91], but those are not discussed in detail here. 
2.3.1 Heritability 
The classic way to study heritability is twin studies [92]. Heritability is the variance of phenotypic variation 
due to genotype. In practice, it is a measure of difference in a certain clinical trait that is explained by the 
genetic difference. It can be calculated from twin studies by the fact that monozygotic twins (MZ) have the 
same genome, whereas dizygotic twins (DZ) share approximately 50% of their genome, in the same way as 
siblings. In twin studies, it is assumed that the twins share mostly the same environmental factors, whereby 
heritability can be estimated. In OM, three twin studies have been conducted, one in the UK, in Norway, and 
in the US (United States).  
The Norwegian Institute for Public Health Twin Study included questions about recurrent OM in their 
questionnaire for their studies conducted in 1992 and 1998. The questionnaire was sent to all Norwegian twins 
born in 1967-1974 and 1967-1979, respectively. The first study included 2750 pairs of twins and estimated the 
h2 to be 74% in females and 45% in males [93]. In the second study, 4247 pairs of twins were available for 
analysis, though no clear sex difference was apparent, h2 was 72% for males and 66% for females [10]. 
Another twin study investigating OM heritability was carried out at the Children’s Hospital of Pittsburgh, 
Pennsylvania, US where a prospective cohort of twins and triplets was recruited between 1982 and 1995. 
Altogether, 168 same-sex twins and 7 sets of same-sex triplets were followed at least every other month for up 
to 5 years. The primary outcome was the proportion of time experiencing MEE. At the 2-year end point, 126 
sets were available for analysis, and h2 was estimated to be 73% [94]. At the 5-year end point, 83 sets were 
available, and the h2 for time experiencing MEE was 72% [9]. 
A third twin study on OM was conducted with the Twin Early Development Study in the UK. Twins born in 
1994 (N=7756) in England and Wales were invited to participate. Parents answered questionnaires when the 
twins were about two, three, and four years old. Questions about OM were indirect, including earache, 
otorrhea, pulling or scratching ears, hearing difficulty, catarrh, mouth-breathing, and snoring. The heritability 
estimates were based on 1373 pairs of same-sex twins that completed all the questionnaires. The h2 for all 
symptoms at ages 2, 3, and 4 were 49%, 66%, and 71%, respectively, but only 57% for AOM-specific (earache, 
otorrhea) questions [8]. 
These studies on the heritability of OM show a considerable genetic component.  
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Figure 2 Candidate genes and positions for OM risk loci from candidate gene studies, linkage studies, GWA studies, and 
a sequencing study. (Figure modified from [95], chromosomes originally created by David Adler, University of Washington)  
2.3.2 Linkage studies 
Four genetic linkage studies have been carried out on OM to find genomic susceptibility loci: three performed 
on two US cohorts, and one performed on two Australian cohorts. 
The first study was based on a Minnesotan (US) family cohort of 591 (238 affected), mainly Caucasian, subjects 
from 133 families. In the study of 404 microsatellite markers, the single-point NPL analysis suggested linkage 
of RAOM and/or COME to genomic loci 10q26.3 (LOD 3.78, p = 3.0 x 10-5) and 19q13.42-q13.43 (LOD 2.61, 
p = 5.3 x 10-4). In conditional analysis of regions 10q and 19q, the genomic loci 3p25.3 showed support for 
linkage (unconditional LOD 0.60, conditional [10q] LOD 2.43, conditional [19q] LOD 1.84) [96]. Later on, the 
locus on chromosome 19 was further studied in an extension of the same cohort. In the NPL analysis of 1091 
SNPs on 607 subjects from 139 families, the association on chromosome 19 was confirmed (LOD 3.75, p = 1.6 
x 10-5). No single SNP revealed significant association in the study. [97] 
In the second linkage study on mainly Caucasian subjects from a Pennsylvanian (US) family cohort of 1506 
subjects from 429 families, NPL analysis was based on the result from 8,802 SNPs. The best result was 
obtained at the genomic loci 17q12 (LOD ~ 4.2, p = 7.0 x 10-5) in the Caucasian-only subgroup. Loci on 4p15.2, 
6p25.1, 7q33, and 10q22.3 were also suggestive of association, and in the analysis of the whole cohort, loci 
10q22.3 became more significant (LOD ~ 3.6, p = 2.6 x 10-4). None of the SNPs showed significant individual 
association with COME or RAOM [98].  
The latest linkage study on OM was performed on two Australian cohorts. Linkage analysis of 23 microsatellites 
from the previously suggested genetic loci 3p25.3, 10q22.3, 10q26.3, 17q12, and 19q13.43 was performed on a 
cohort of 468 subjects (208 affected) from 101 families. They replicated the linkage of OM to 10q26.3 
(Zlr = 2.69, p = 0.0036) and also showed suggestive linkage to 10q22.3 (Zlr = 1.64, p = 0.05). In fine-mapping 
of the region 10q26.3, 10,185 SNPs (2,270 genotyped, 7,915 imputed) were analyzed on another cohort of 256 
affected cases and 575 controls. No SNP reached significance after Bonferroni correction (p < 4.9 x 10-6), but, 
using a more relaxed threshold (p < 10-3), 38 SNPs were associated: 9 in intergenic regions and the rest in 
intronic regions of three genes (ADAM1, DOCK1, and TCERG1L). The best result was for the intergenic marker 
rs7922424 (p = 9.47 x 10-6), between the genes TCERG1L and PPP2R2D. Through expression and in silico 
analyses, the authors concluded that PPP2R2D was the most plausible OM risk gene in the region 10q26.3 
[99]. 
Taken together, based on the linkage studies on OM, the loci 17q12, 10q, and 19q13 seem to have the strongest 
evidence.  
2.3.3 Candidate gene studies 
The candidate gene approach has been a common tool for genetic studies over the past 20 years, and genetic 
studies on OM are no exception. The studies have been made on both common and rare variants, in both coding 
and non-coding regions of the genes. The sample sizes have mostly been quite small (most <100 cases and 
controls) and the phenotype definition has varied between the studies. Most of the studies have focused on 
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innate immunity genes and cytokines. The studies have been reviewed several times [95, 100-105], thus, here 
only the positive findings are presented (Table 2). 
As early as 1983, a genetic study on OM was conducted. In the study, ABO blood groups of 610 children with 
COME and 361 patients with cholesteatoma were compared to 25,877 blood donors. Blood group A proved to 
be more common and blood group B less prevalent, among patients with COME compared to controls. The 
authors concluded from the results that it may indicate that there is a genetic risk factor for OM [106]. Another 
early candidate gene study was performed on the human leukocyte antigen (HLA) types. HLA-A2 and HLA-
A3 were associated with RAOM, whereas in patients with COME, the HLA-A2 frequency was much lower than 
in patients with RAOM. These associations were interpreted to indicate genetic predisposition to OM [107, 
108]. 
Studies on genes in the innate immunity system 
The mechanisms of innate immunity are well developed at birth and serve as a first line of defense. Innate 
immunity functions non-specifically in several ways: identifying foreign material, activating the complement 
system, initializing the inflammatory process, and working as a barrier. It has an essential role in the young 
child when the role of the maternal immunity has decreased, and before the adaptive immunity has developed. 
Therefore, genes of innate immunity could be plausible risk genes for OM, since it is a common childhood 
disease [109]. 
MBL 
Mannose-binding lectins (MBL) bind to foreign material and initiate the complement pathway. MBL genes 
have been associated with the risk of URIs in young children [110]. In a Dutch cohort of 244 children, the wild 
type of a four-marker haplotype in the promoter and first exon region of the MBL2 gene was associated with a 
lower risk of AOM in the subgroup of 113 children aged 12 - 24 months [111]. In 17 Belgian children with RAOM 
or COME, one six-marker haplotype and one four-marker haplotype in the promoter and first exome region 
was overrepresented, compared to 172 healthy subjects [112]. The issue remains inconclusive, however, as a 
US family study was unable to replicate these findings [113].  
TLR 
Toll-like receptors (TLR) are pattern-recognition receptors in the innate immunity system. They initiate the 
signaling pathway which then starts the inflammatory response [114]. In a Dutch cohort, the G-allele of the 
rs4986790 (Asp299Gly) marker in the exon of TLR4 was protective against AOM in children under four [115]. 
In subsequent studies of the same rare polymorphism, the association with OM risk did not replicate [113, 116, 
117], but it has been shown that the A/G variant is associated with Moraxella catarrhalis colonization, which 
is a common OM pathogen [118]. In a Minnesota-based family cohort, the variant rs2770146 in the intron of 
TLR4 was associated with COME and/or RAOM, but the result could not be replicated by the same study group 
in a Pennsylvania-based family cohort [113]. In a small US cohort, there was a trend toward association with 
variants in the TLR4 region [119]. Several candidate gene studies on TLR2 association with OM have been 
conducted, but only one that showed association; the TLR2 Arg753Gln polymorphism was more common in 
patients with CSOM, compared to controls [113, 115, 117, 120, 121]. 
CD14 
CD14 (cluster of differentiation 14) has several functions in the innate immunity, one of which is being a co-
receptor for TLR4. It can either be attached to monocytes or exist as a soluble protein. Among young children 
in a Dutch cohort, the TT-genotype of rs2569190 in the CD14 gene’s 5’ non-coding region was protective for 
AOM, compared with the CC-genotype [122]. The result, however, has not been replicated in other cohorts 
[113, 117].  
Surfactant 
Surfactants were first recognized as tension-reducing phospholipoproteins in the lungs. Later on, their 
expression has been detected in other parts of the body, including the middle ear. They play a role in 
opsonization in the innate immunity [123]. The first genetic study on Surfactant A (SFTPA) polymorphisms in 
OM was conducted on Finnish children with RAOM. A two-marker haplotype in the coding region of the gene 
was more common in the RAOM group and in those with their first AOM before the age of 6 months, compared 
with controls. The homozygotes for one coding variant in SFTPA1 were significantly less frequent among those 
with their first AOM before the age of 6 months, compared to controls [124]. In a US cohort of Caucasian 
children, the opposite was found; the same haplotype showed a protective association against any OM during 
the first 12 months of life, while another SFTPA1 variant was associated with a higher number of OM episodes 
during the first 12 months of life [125]. In another US cohort, no significant genetic association was found 
between SFTPA1 and RAOM or COME. On the other hand, they found an association for the coding variant 
rs1051246 of surfactant D (SFTPD), but could not replicate the finding in another US cohort [113]. 
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Other innate immunity genes 
The protein transcribed by the gene SLC11A1 (Solute carrier family 11 member 1) functions in the innate 
immunity system as a transporter in the clearance of intracellular pathogens. In an Australian cohort of 531 
families (660 affected children), they found evidence of an association between four polymorphisms in the 
promoter and intron region of SLC11A1 and RAOM/COME [126]. After pneumococcal vaccination of the study 
participants in a Dutch cohort, the coding variant rs1801274 (His131Arg) in the FCGR2A (Fc Gamma Receptor 
IIa) was associated with an increase in RAOM [127]. 
Cytokines 
Cytokines serve as molecules for intercellular signaling. They regulate a vast amount of biological events, 
including immune responses. Genetic variants of the cytokines interleukin 6 (IL6), IL10, IL1α, transforming 
growth factor beta 1 (TGFβ1), interferon gamma (IFNγ), and tumor necrosis factor alpha (TNFα) have been 
associated with a risk of OM. 
Interleukin 6 
The association between OM and IL6, mainly the rs1800795 (-274) polymorphism in an intronic region, has 
been extensively investigated. The first significant association was reported in a US cohort where the G/C or 
C/C polymorphism was associated with OM susceptibility [128]. As the cohort was prospectively followed, 
those with the high cytokine-producing allele of rs1800795 were more likely to be OM susceptible [129]. In 
another US cohort of children, the homozygote C genotype of rs1800795 was a significant predictor of OM 
during RV infection [130]. In a Dutch study, they found the opposite association of the rs1800795 homozygote 
G genotype to RAOM in children [115]. The matter remains inconclusive as the association is absent in several 
studies [131-133].  
Interleukin 10 
In a Dutch cohort who received the pneumococcal vaccination, the homozygote A allele of rs1800896 (-1082) 
in the IL10 promoter region was associated with protection against RAOM [115]. The result in a US study was 
in line with the Dutch result, showing that the high producing IL10 haplotype consisting of rs1800896, 
rs1800871 (-819), and rs1800872 (-592), in the promoter region, was a significant predictor for OM during 
RSV and RV infection [130]. Additionally, in a Greek cohort, the alternative alleles of the same haplotype of 
IL10 were associated with more AOMs and insertions of tympanostomy tubes compared to those with the wild 
type [134]. Likewise, the alternative variant of rs1800896 in IL10 was associated with OM proneness in a US 
cohort [135]. Despite the positive findings, however, several studies have failed to replicate the association [113, 
131, 132]. 
Other interleukins 
In a small subgroup of Finnish patients with RAOM but no history of atopic diseases, the frequency of allele 1 
of rs1800587 (-899) in the 5’ non-coding region of IL1α was significantly higher in patients versus controls 
[136]. The rs1143634 (+3953) in the coding region of IL1β has been associated with a higher symptom score in 
AOM and URI [133]. Additionally, the rs16944 (-511) variant upstream of IL1β has been associated with otitis 
proneness [135]. On the other hand, several studies have found a lack of evidence for an association between 
IL1β and OM [113, 115, 128, 136]. 
The TGFβ pathway 
In a US cohort of young children, the high producing TGFβ1 genotype (not specified which polymorphism) was 
more frequent among those with OM during URIs [132]. In a Greek cohort, the alternative genotype of TGFβ1 
(codon 10) was associated with more AOM episodes and insertion of tympanostomy tubes, though, it was also 
associated with an increased age at the first AOM [134]. Altogether, 22 SNPs from 6 genes in the TGFβ1 
pathway were investigated by an Australian study group. They showed significant association between severe 
OM and the genes F-box only protein 1 (FBXO11), SMAD2, and SMAD4. The association in the intronic region 
of FBXO11 was replicated in another Australian cohort, but not the SMAD associations [137]. In a US study, 
the intronic FBXO11 marker rs2134056 was associated with COME and RAOM [138]. In a UK family study, 
SMAD2 and FBXO11 were associated with COME [139]. In line with the previous results, alleles rs8097137 
(intergenic) and rs17663887 (intron) in the SMAD2 and SMAD4 genes showed a trend toward association in 
a small US cohort [119]. On the other hand, among US children with RSV infection, no association existed 
between OM and TGFβ1 genotypes [131]. 
Tumor necrosis factor α 
One of the most extensively studied cytokines is TNFα, mainly the rs1800629 (-308) polymorphism in the 
promoter region of the gene. In a US cohort, the G/A or A/A genotypes of rs1800629 were associated with an 
increased risk of OM [128]. It was also a predictor for AOM during RV infection and other URIs [129, 130]. 
Contrary to these findings, three other independent groups did not find this association [131-133, 136]. In a 
Dutch cohort, the frequency of two other variants in the TNFα promoter region, G/G of rs361525 (-238) and 
 Review of the Literature 
 25 
G/G of rs1800750 (-376), were associated with otitis proneness in children, especially in children under the 
age of four [115].  
Other cytokines 
Among patients with RSV, the A/A genotype of the intronic rs2430561 (+874) IFNγ variant was associated 
with a higher incidence AOM [131]. The result, however, did not replicate in two other studies [130, 132]. The 
A-allele of the Thr280Met (rs3732378) polymorphism in the second exome of the chemokine receptor CX3CR1 
(chemokine (C-X3-C motif) receptor 1) was associated with OM proneness [135]. 
Mucins 
Mucins (MUC) are glycosylated proteins and are the main components of extracellular gels. They belong to the 
mucociliary transport system that preserves the ventilated state of the middle ear [140]. Mucins have been 
proposed as candidate risk genes in OM due to their over-expression in the MEE fluid of patients with COME 
[141]. The T-allele of rs7396030 in the intron 16 region of MUC2 was associated with OM risk in a US family 
cohort, but in another US cohort the association was to the opposite C-allele. Also, the T-allele of variants 
rs2075859 in exon 9 and rs2735733 in intron 30 in the MUC5AC, MUC5B genes were associated in the initial 
cohort, but the result could not be confirmed in the replication cohort [113]. In a small US cohort, the b-allele 
(Southern blot analysis, polymorphisms not determined) of MUC5AC was more prevalent in patients with 
COME, compared to RAOM [142]. The intergenic variant rs4963049 in the MUC5AC/B gene showed a trend 
toward association in a small US cohort [119]. 
Other candidate genes 
Other candidate genes associated with OM include various categories of genes. Sodium channel subunit beta-
1 (SCN1B) codes for a component in the voltage-gated sodium channels. The A–allele of the rs8100085 variant 
in SCN1B’s intronic region was associated with RAOM and COME in a US cohort, but the result did not 
replicate in a follow-up cohort [113]. In the HVRII-region of mtDNA, the C-allele of T195C was associated with 
an increased risk of OM in a Czech cohort [143]. Plasminogen activator inhibitor-1 (PAI1), also known as 
SERPINE1, functions in inflammation by inhibiting cellular migration and invasion. Its association with 
numerous diseases has been studied extensively. In a Dutch cohort, the 4G/4G allele of rs1799889 in the PAI1 
promoter was associated with an increased risk for RAOM [144]. Carnitine palmitoyltransferase type 1A 
(CPT1A) is a liver enzyme that has a role in fatty acid oxidation. The children who were homozygous for the 
coding variant, the so-called “arctic variant”, c.1436 C>T (rs80356779) of CPT1A in rural communities in 
Western and Northern Alaska were more likely to have OM and lower respiratory tract infections [145]. 
Taken together, although an abundant number of candidate gene studies have been carried out on the complex 
disease of childhood OM, not many conclusions can be drawn. The studies are very heterogeneous and, 
therefore, the results vary between cohorts and populations. Many of the studies are vastly underpowered. For 
instance, for the well-studied TNFα variant rs1800629 (MAF 0.09), the power to detect a finding of OR 1.3 in 
200 affected cases and 200 healthy controls is only 20% for p < 0.05 [146]. Still, up until very recently, 
underpowered studies with results left uncorrected for multiple testing were published in good journals [147]. 
Several candidate gene studies have been performed on cohorts as small as 40 affected cases and for rare 
variants with MAF < 0.05. Therefore, one should be cautious about the clinical meaning of those results. 
Additionally, some of the studies do not have a control population, but are only studying disease severity in the 
setting of the genotype. Very few of the studies include replications, and almost none include functional 
analyses. Another drawback is that the criteria for an affected case varies between the studies. For instance, in 
one of the Australian cohorts, a history of ≥3 AOM episodes before the age of three was considered as RAOM 
[137], whereas the more commonly accepted criterion is ≥3 AOMs in 6 months, or ≥4 AOMs during 12 months. 
The level of significance is also questionable in most of the studies, as only in some have the p-values been 
corrected for multiple tests. Yet another dilemma is that many of the early studies do not use the international 
classifications of SNPs with rs-numbers, making it difficult to compare the results on a gene. Functional studies 
on the genetic findings are also lacking. Future studies on genetic risk factors for OM require large cohorts with 
well-defined phenotypes. 
2.3.4 GWA 
A GWA study is a powerful hypothesis-free tool to identify new, common (frequency > 5%), low-risk (OR < 1.5) 
markers for complex diseases. To date, two GWA studies have been performed on OM.  
The first GWA study on OM was performed in an Australian OM cohort of 416 affected subjects and 1,075 
controls on the Illumina 660W-Quad chip. In the analysis of 2,524,817 SNPs (535,544 genotyped, 1,989,273 
imputed), no SNP reached genome-wide significance (p < 10-8), and they failed to replicate the top findings in 
a subsequent study in another Australian family cohort and in a US cohort [148, 149]. 
The second GWA study was performed on the Illumina Human CNV370-Duo Bead Chip on the Minnesota, US 
cohort of 143 families with 602 subjects (373 affected). For the initial analysis, 324,748 SNPs were available, 
but none showed significant association (p < 10-8). When the top results were studied on the Sequenom 
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platform on the Pennsylvania, US, cohort of 441 families with 1584 study subjects (932 affected), the intergenic 
marker rs10497394 in a large intergenic region on chromosome 2q31.1 between the genes CDCA7 and SP3 was 
significant (pmeta-analysis = 1.52 x 10-8). The region contains many regulatory and genomic elements that might 
have functional effects. In silico analysis found that the marker regulates expression of LDLR (Low-density 
lipoprotein receptor) on chromosome 19. LDLR is a binding site for RV, which is a common pathogen 
preceding AOM. LDLR is expressed on ciliated airway epithelial cells, and it had earlier been found to be 
associated with the pathogenesis of asthma in mice [150]. 
2.3.5 Sequencing 
Sequencing, especially exome sequencing, has become more affordable and available in recent years. It is 
predominantly used to find rare variants with high impact on the phenotype studied. To date, only one exome 
sequencing study has been published on OM. By exome sequencing the DNA of two second cousins who have 
CSOM in a Filipino isolate, where the OM prevalence is almost 50%, a variant of A2ML1 (α2-macroblobulin-
like 1) was revealed as a new genetic risk variant for OM. The variant is a duplication (p.Ser829Trpfs*9), and 
the result was confirmed by Sanger sequencing of 51 other individuals from the same pedigree (LOD 7.5). The 
variant was also detected in 3 individuals with early-onset OM in a US cohort. A2ML1 is expressed in the middle 
ear of mice, thus supporting it as a rare, but high risk variant for OM [151]. Variants of A2ML1 (p.Arg802Leu, 
p.Arg592Leu, and p.Arg802His) have also been found in patients with Noonan syndrome [152], a syndrome 
that includes congenital heart anomalies, short stature, facial dysmorphism, chest deformity, cryptorchidism, 
learning difficulties, and hearing loss. A substantial part of the hearing loss in Noonan syndrome is accounted 
for by COME, strengthening the hypothesis that A2ML1 could confer genetic risk in OM [153].  
OM is a complex disease where genetic risk is indisputable. The genetic risk is complex and probably based on 
both common variants with a low risk effect (e.g., FBXO11 variants) and rare variants with high risk (e.g., 
A2ML1 variants). Previous candidate gene and GWA studies have been inconclusive, underpowered, and have 
utilized various phenotypes. Most of the genetic studies on OM have been performed on Caucasian populations 
with RAOM and COME as the diagnoses. In the developing world, CSOM is still common, but only a few studies 
have investigated that phenotype. Finding genetic risk variants for OM in well-performed genetic studies with 
significant results that are confirmed by functional studies could help in the understanding of OM 
pathogenesis, characterize the high risk patients, and aid in development of new methods for prevention and 
treatment of this common disease. 
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50
6 
A
U
 
2 
C
G
 
>
3 
A
O
M
s 
by
 th
e 
ag
e 
of
 3
 y
r 
C
a=
25
3;
 C
o=
86
6 
O
R
=
1.
38
; p
=
0.
00
74
 
[1
37
] 
F
B
X
O
11
 
rs
67
28
84
3 
A
U
 
2 
C
G
 
>
3 
A
O
M
s 
by
 th
e 
ag
e 
of
 3
 y
r 
C
a=
25
3;
 C
o=
86
6 
O
R
=
1.
39
; p
=
0.
00
61
 
[1
37
] 
F
B
X
O
11
 
rs
96
01
06
 
U
K
 
2 
C
G
 
C
O
M
E
 
50
0 
tr
io
s 
p(
be
st
)<
0.
01
30
 
[1
39
] 
F
B
X
O
11
 
rs
21
34
05
6 
U
S 
2 
C
G
 
R
A
O
M
/C
O
M
E
 
14
2 
fa
m
ili
es
 
p=
0.
02
 
[1
38
] 
F
C
G
R
2A
 
rs
18
01
27
4 
N
L 
1 
C
G
 
N
um
be
r 
of
 O
M
s 
af
te
r 
PV
 
C
a=
38
3;
 n
o 
co
nt
ro
ls
 
R
R
=
1.
77
; p
=
0.
03
;  
[1
27
] 
G
R
ID
2 
rs
11
09
73
83
 
A
U
 
4 
G
W
A
 
>
3 
A
O
M
s 
by
 th
e 
ag
e 
of
 3
 y
r 
C
a=
41
6;
 C
o=
10
75
 
O
R
=
1.
43
; p
=
4.
7x
10
-5
 
[1
48
] 
H
L
A
-A
2 
H
LA
-A
2 
SW
 
6 
C
G
 
R
A
O
M
 
C
a=
45
; C
o=
22
 
p<
0.
05
 
[1
08
] 
H
L
A
-A
3 
H
LA
-A
3 
SW
 
6 
C
G
 
R
A
O
M
 
C
a=
45
; C
o=
22
 
p<
0.
05
 
[1
08
] 
H
V
R
II
 
re
gi
on
 o
n
 
m
tD
N
A
 
T
19
5C
 
C
R
 
m
t 
C
G
 
N
um
be
r 
of
 A
O
M
s 
C
a=
35
5 
R
R
=
1.
62
; p
=
0.
03
2 
[1
43
] 
IF
N
γ 
rs
24
30
56
1 
U
S 
12
 
C
G
 
O
M
 w
it
h 
R
SV
 in
fe
ct
io
n 
C
a=
20
; C
o=
57
 
χ2
=
4.
2;
 p
=
0.
04
 
[1
31
] 
IL
10
 
rs
15
54
28
6 
U
S 
1 
C
G
 
R
A
O
M
/C
O
M
E
 
14
2 
fa
m
ili
es
 
p(
ht
)=
0.
01
2 
[1
54
] 
IL
10
 
rs
18
00
87
1 
U
S 
1 
C
G
 
O
M
 e
pi
so
de
 fo
llo
w
in
g 
R
SV
/R
V
 
C
a=
10
2;
 C
o=
98
 
O
R
=
2.
9;
 p
=
0.
05
 
[1
35
] 
IL
10
 
rs
18
00
87
2 
U
S 
1 
C
G
 
O
M
 e
pi
so
de
 fo
llo
w
in
g 
R
SV
/R
V
 
C
a=
10
2;
 C
o=
98
 
O
R
=
2.
9;
 p
=
0.
05
 
[1
35
] 
IL
10
 
rs
18
00
87
2 
U
S 
1 
C
G
 
R
A
O
M
/C
O
M
E
 
14
2 
fa
m
ili
es
 
p(
ht
)=
0.
03
9 
[1
54
] 
IL
10
 
rs
18
00
89
0 
U
S 
1 
C
G
 
R
A
O
M
/C
O
M
E
 
14
2 
fa
m
ili
es
 
p(
ht
)=
0.
01
7 
[1
54
] 
IL
10
 
rs
18
00
89
3 
U
S 
1 
C
G
 
R
A
O
M
/C
O
M
E
 
14
2 
fa
m
ili
es
 
p(
ht
)=
0.
01
7 
[1
54
] 
IL
10
 
rs
18
00
89
6 
N
L 
1 
C
G
 
Pr
ot
ec
ti
ve
 fo
r 
A
O
M
 a
ft
er
 P
V
 
C
a=
34
8;
 C
o=
46
3 
p=
0.
01
 
[1
15
] 
IL
10
 
rs
18
00
89
6 
U
S 
1 
C
G
 
O
M
 e
pi
so
de
 fo
llo
w
in
g 
R
SV
/R
V
 
C
a=
10
2;
 C
o=
98
 
O
R
=
2.
9;
 p
=
0.
00
5 
[1
35
] 
IL
10
 
rs
18
00
89
6 
U
S 
1 
C
G
 
R
A
O
M
/C
O
M
E
 
14
2 
fa
m
ili
es
 
p(
ht
)=
0.
01
7 
[1
54
] 
  
R
ep
or
te
d 
po
si
ti
ve
 g
en
et
ic
 a
ss
oc
ia
ti
on
s 
w
it
h 
O
M
 in
 p
re
vi
ou
s 
st
ud
ie
s 
Gene 
Marker 
Country 
Chromosome 
Study setting 
Phenotype 
Samples 
Result 
Ref 
IL
10
 
rs
30
24
50
9 
U
S 
1 
C
G
 
R
A
O
M
/C
O
M
E
 
14
2 
fa
m
ili
es
 
p=
0.
04
0 
[1
54
] 
IL
10
 
rs
18
00
87
1 
G
R
 
1 
C
G
 
O
ns
et
 o
f A
O
M
, n
um
be
r 
of
 A
O
M
s 
C
a=
96
, n
o 
co
nt
ro
ls
 
p<
0.
00
01
 
[1
34
] 
IL
10
 
rs
18
00
87
2 
U
S 
1 
C
G
 
O
M
 p
ro
ne
ne
ss
 
C
a=
65
3;
 n
o 
co
nt
ro
ls
 
O
R
=
1.
54
 
[1
35
] 
IL
1β
  
rs
11
43
63
4 
U
S 
2 
C
G
 
Se
ve
ri
ty
 o
f T
M
 in
fla
m
m
at
io
n 
af
te
r 
A
O
M
 
C
a=
10
4;
 C
o=
24
 
p=
0.
02
 
[1
35
] 
IL
1α
 
rs
18
00
58
7 
FI
 
2 
C
G
 
A
O
M
 e
pi
so
de
s 
C
a=
46
; C
o=
40
0 
p=
0.
03
 
[1
36
] 
IL
1β
 
rs
16
94
4 
U
S 
2 
C
G
 
O
M
 p
ro
ne
ne
ss
 
C
a=
65
3;
 n
o 
co
nt
ro
ls
 
O
R
=
1.
35
 
[1
35
] 
IL
6 
rs
18
00
79
5 
N
L 
7 
C
G
 
≥
2 
A
O
M
 
C
a=
34
7;
 C
o=
46
0 
O
R
 >
1.
45
; p
=
0.
02
 
[1
15
] 
IL
6 
rs
18
00
79
5 
U
S 
7 
C
G
 
R
A
O
M
 
C
a=
68
; C
o=
14
5 
p<
0.
01
 
[1
29
] 
IL
6 
rs
18
00
79
5 
U
S 
7 
C
G
 
≥
3 
A
O
M
s/
6 
m
on
th
s 
or
 ≥
4 
A
O
M
s/
ye
ar
 
C
a=
19
2;
 C
o=
19
2 
O
R
=
1.
57
; p
=
0.
03
 
[1
32
] 
IL
6 
rs
18
00
79
5 
U
S 
7 
C
G
 
A
O
M
 e
pi
so
de
 fo
llo
w
in
g 
R
SV
/R
V
 
C
a=
77
; C
o=
80
 
O
R
=
0.
47
; p
<
0.
01
 
[1
35
] 
In
te
rg
en
ic
 
rs
10
00
80
15
 
A
U
 
4 
G
W
A
 
>
3 
A
O
M
s 
by
 th
e 
ag
e 
of
 3
 y
r 
C
a=
41
6;
 C
o=
10
75
 
O
R
=
1.
47
; p
=
2.
3x
10
-5
 
[1
48
] 
In
te
rg
en
ic
 
rs
10
49
73
94
 
U
S 
2 
G
W
A
 
R
A
O
M
/C
O
M
E
 
14
3 
fa
m
ili
es
; C
a=
37
3 
p=
2.
9x
10
-5
 
[1
50
] 
In
te
rg
en
ic
 
rs
10
49
90
06
 
U
S 
6 
G
W
A
 
R
A
O
M
/C
O
M
E
 
14
3 
fa
m
ili
es
; C
a=
37
3 
p=
2.
1x
10
−
6  
[1
50
] 
In
te
rg
en
ic
 
rs
13
43
89
48
 
A
U
 
8 
G
W
A
 
>
3 
A
O
M
s 
by
 th
e 
ag
e 
of
 3
 y
r 
C
a=
41
6;
 C
o=
10
75
 
O
R
=
1.
82
; p
=
1.
2x
10
-5
 
[1
48
] 
In
te
rg
en
ic
 
rs
14
96
30
6 
A
U
 
8 
G
W
A
 
>
3 
A
O
M
s 
by
 th
e 
ag
e 
of
 3
 y
r 
C
a=
41
6;
 C
o=
10
75
 
O
R
=
1.
86
; p
=
1.
3x
10
-6
 
[1
48
] 
In
te
rg
en
ic
 
rs
18
59
16
1 
A
U
 
4 
G
W
A
 
>
3 
A
O
M
s 
by
 th
e 
ag
e 
of
 3
 y
r 
C
a=
41
6;
 C
o=
10
75
 
O
R
=
1.
84
; p
=
1.
6x
10
-6
 
[1
48
] 
In
te
rg
en
ic
 
rs
18
94
51
6 
A
U
 
X
 
G
W
A
 
>
3 
A
O
M
s 
by
 th
e 
ag
e 
of
 3
 y
r 
C
a=
41
6;
 C
o=
10
75
 
O
R
=
1.
37
; p
=
6.
6x
10
-6
 
[1
48
] 
In
te
rg
en
ic
 
rs
21
32
52
8 
A
U
 
8 
G
W
A
 
>
3 
A
O
M
s 
by
 th
e 
ag
e 
of
 3
 y
r 
C
a=
41
6;
 C
o=
10
75
 
O
R
=
1.
86
; p
=
1.
3x
10
-6
 
[1
48
] 
In
te
rg
en
ic
 
rs
64
38
77
9 
U
S 
3 
G
W
A
 
R
A
O
M
/C
O
M
E
 
14
3 
fa
m
ili
es
; C
a=
37
3 
p=
2.
9×
10
−
6  
[1
50
] 
In
te
rg
en
ic
 
rs
78
46
28
4 
A
U
 
8 
G
W
A
 
>
3 
A
O
M
s 
by
 th
e 
ag
e 
of
 3
 y
r 
C
a=
41
6;
 C
o=
10
75
 
O
R
=
1.
76
; p
=
1.
6x
10
-5
 
[1
48
] 
In
te
rg
en
ic
 
rs
78
46
68
4 
A
U
 
8 
G
W
A
 
>
3 
A
O
M
s 
by
 th
e 
ag
e 
of
 3
 y
r 
C
a=
41
6;
 C
o=
10
75
 
O
R
=
1.
62
; p
=
5.
2x
10
-5
 
[1
48
] 
In
te
rg
en
ic
 
rs
95
64
89
7 
A
U
 
13
 
G
W
A
 
>
3 
A
O
M
s 
by
 th
e 
ag
e 
of
 3
 y
r 
C
a=
41
6;
 C
o=
10
75
 
O
R
=
1.
78
; p
=
1.
9x
10
-5
 
[1
48
] 
 
R
ep
or
te
d 
po
si
ti
ve
 g
en
et
ic
 a
ss
oc
ia
ti
on
s 
w
it
h 
O
M
 in
 p
re
vi
ou
s 
st
ud
ie
s 
 
Gene 
Marker 
Country 
Chromosome 
Study setting 
Phenotype 
Samples 
Result 
Ref 
K
IF
7 
rs
11
10
06
0 
U
S 
15
 
G
W
A
 
R
A
O
M
/C
O
M
E
 
14
3 
fa
m
ili
es
; C
a=
37
3 
p=
9.
1x
10
−
7  
[1
50
] 
L
IN
28
 
rs
12
72
89
00
 
A
U
 
1 
G
W
A
 
>
3 
A
O
M
s 
by
 th
e 
ag
e 
of
 3
 y
r 
C
a=
41
6;
 C
o=
10
75
 
O
R
=
1.
75
; p
=
2.
41
x1
0-
5  
[1
48
] 
M
B
L
2 
 
rs
11
00
31
25
 
B
E
 
10
 
C
G
 
≥
3 
A
O
M
/y
ea
r 
C
a=
17
; C
o=
17
2 
O
R
(h
t)
=
2.
9 
 
[1
12
] 
M
B
L
2 
rs
18
00
45
0 
N
L 
10
 
C
G
 
M
ea
n 
A
O
M
 e
pi
so
de
s 
C
a=
32
; C
o=
81
 
p(
ht
)=
0.
02
7 
[1
11
] 
M
B
L
2 
 
rs
18
00
45
0 
B
E
 
10
 
C
G
 
≥
3 
A
O
M
/y
ea
r 
C
a=
17
; C
o=
17
2 
O
R
(h
t)
=
2.
9 
 
[1
12
] 
M
B
L
2 
rs
18
00
45
1 
N
L 
10
 
C
G
 
M
ea
n 
A
O
M
 e
pi
so
de
s 
 
C
a=
32
; C
o=
81
 
p(
ht
)=
0.
02
7 
[1
11
] 
M
B
L
2 
 
rs
18
00
45
1 
B
E
 
10
 
C
G
 
≥
3 
A
O
M
/y
ea
r 
C
a=
17
; C
o=
17
2 
O
R
(h
t)
=
2.
9 
 
[1
12
] 
M
B
L
2 
rs
50
30
73
7 
N
L 
10
 
C
G
 
M
ea
n 
A
O
M
 e
pi
so
de
s 
 
C
a=
32
; C
o=
81
 
p(
ht
)=
0.
02
7 
[1
11
] 
M
B
L
2 
 
rs
50
30
73
7 
B
E
 
10
 
C
G
 
≥
3 
A
O
M
/y
ea
r 
C
a=
17
; C
o=
17
2 
O
R
(h
t)
=
2.
9 
 
[1
12
] 
M
B
L
2 
 
rs
70
95
89
1 
B
E
 
10
 
C
G
 
≥
3 
A
O
M
/y
ea
r 
C
a=
17
; C
o=
17
2 
O
R
(h
t)
=
2.
9 
 
[1
12
] 
M
B
L
2 
rs
70
96
20
6 
N
L 
10
 
C
G
 
M
ea
n 
A
O
M
 e
pi
so
de
s 
 
C
a=
32
; C
o=
81
 
p(
ht
)=
0.
02
7 
[1
11
] 
M
B
L
2 
 
rs
70
96
20
6 
B
E
 
10
 
C
G
 
≥
3 
A
O
M
/y
ea
r 
C
a=
17
; C
o=
17
2 
O
R
(h
t)
=
2.
9 
 
[1
12
] 
M
B
L
2 
rs
93
05
07
 
N
L 
10
 
C
G
 
M
ea
n 
A
O
M
 e
pi
so
de
s 
 
C
a=
32
; C
o=
81
 
p(
ht
)=
0.
02
7 
[1
11
] 
M
U
C
2 
rs
73
96
03
0 
U
S 
11
 
C
G
 
R
A
O
M
/C
O
M
E
 
14
2 
fa
m
ili
es
 
p=
0.
04
9 
[1
13
] 
M
U
C
2 
rs
73
96
03
0 
U
S 
11
 
C
G
 
R
A
O
M
/C
O
M
E
 
44
1 
fa
m
ili
es
 
p=
0.
02
2 
[1
13
] 
M
U
C
5B
 
rs
49
63
04
9 
U
S 
11
 
C
G
 
C
O
M
E
 
C
a=
10
2;
 C
o=
83
 
p(
ua
)=
0.
03
3 
[1
19
] 
M
U
C
5A
C
 
M
U
C
5A
C
-b
 
U
S 
11
 
C
G
 
R
A
O
M
/C
O
M
E
 
C
a=
40
; C
o=
40
 
p=
0.
02
5 
[1
42
] 
M
U
C
5B
 
rs
20
75
85
9 
U
S 
11
 
C
G
 
R
A
O
M
/C
O
M
E
 
14
2 
fa
m
ili
es
 
p=
0.
04
1 
[1
13
] 
M
U
C
5B
 
rs
27
35
73
3 
U
S 
11
 
C
G
 
R
A
O
M
/C
O
M
E
 
14
2 
fa
m
ili
es
 
p=
0.
00
2 
[1
13
] 
M
U
C
5B
 
rs
27
35
73
3 
U
S 
11
 
C
G
 
R
A
O
M
/C
O
M
E
 
14
2 
fa
m
ili
es
 
p=
0.
04
1 
[1
54
] 
P
R
K
G
1 
rs
45
75
21
3 
A
U
 
10
 
G
W
A
 
>
3 
A
O
M
s 
by
 th
e 
ag
e 
of
 3
 y
r 
C
a=
41
6;
 C
o=
10
75
 
O
R
=
1.
53
; p
=
2.
5x
10
-5
 
[1
48
] 
R
O
R
2 
rs
11
79
08
08
 
A
U
 
9 
G
W
A
 
>
3 
A
O
M
s 
by
 th
e 
ag
e 
of
 3
 y
r 
C
a=
41
6;
 C
o=
10
75
 
O
R
=
1.
41
; p
=
4.
7x
10
-5
 
[1
48
] 
S
C
N
1B
 
rs
81
00
08
5 
U
S 
19
 
C
G
 
R
A
O
M
/C
O
M
E
 
14
2 
fa
m
ili
es
 
p=
0.
01
3 
[1
13
] 
  
R
ep
or
te
d 
po
si
ti
ve
 g
en
et
ic
 a
ss
oc
ia
ti
on
s 
w
it
h 
O
M
 in
 p
re
vi
ou
s 
st
ud
ie
s 
Gene 
Marker 
Country 
Chromosome 
Study setting 
Phenotype 
Samples 
Result 
Ref 
S
E
R
P
IN
E
1 
rs
17
99
88
9 
N
L 
7 
C
G
 
2–
3 
A
O
M
s 
vs
. ≥
4 
A
O
M
s 
C
a=
22
6;
 C
o=
12
2 
O
R
=
1.
87
; p
=
0.
02
 
[1
44
] 
S
F
T
P
A
1 
rs
10
59
04
7 
U
S 
10
 
C
G
 
O
M
 in
 fi
rs
t y
ea
r 
of
 li
fe
 
C
a=
25
8;
 C
o=
97
 
O
R
(h
t)
=
0.
23
  
[1
25
] 
S
F
T
P
A
1 
rs
10
59
05
7 
U
S 
10
 
C
G
 
O
M
 in
 fi
rs
t y
ea
r 
of
 li
fe
 
C
a=
25
8;
 C
o=
97
 
O
R
(h
t)
=
0.
23
  
[1
25
] 
S
F
T
P
A
1 
rs
11
36
45
0 
U
S 
10
 
C
G
 
O
M
 in
 fi
rs
t y
ea
r 
of
 li
fe
 
C
a=
25
8;
 C
o=
97
 
O
R
(h
t)
=
0.
23
  
[1
25
] 
S
F
T
P
A
1 
rs
11
36
45
1 
U
S 
10
 
C
G
 
O
M
 in
 fi
rs
t y
ea
r 
of
 li
fe
 
C
a=
25
8;
 C
o=
97
 
O
R
(h
t)
=
0.
23
  
[1
25
] 
S
F
T
P
A
1 
rs
42
53
52
7 
U
S 
10
 
C
G
 
O
M
 in
 fi
rs
t y
ea
r 
of
 li
fe
 
C
a=
25
8;
 C
o=
97
 
O
R
(h
t)
=
0.
23
  
[1
25
] 
S
F
T
P
A
1/
SF
T
P
A
2 
6A
4-
1A
 
ha
pl
ot
yp
e 
FI
 
10
 
C
G
 
R
A
O
M
 
C
a=
14
7;
 C
o=
27
8 
p(
ht
)=
0.
03
 
[1
24
] 
S
F
T
P
A
2 
rs
10
59
04
6 
U
S 
10
 
C
G
 
O
M
 in
 fi
rs
t y
ea
r 
of
 li
fe
 
C
a=
25
8;
 C
o=
97
 
O
R
(h
t)
=
0.
23
  
[1
25
] 
S
F
T
P
A
2 
rs
19
65
70
7 
U
S 
10
 
C
G
 
O
M
 in
 fi
rs
t y
ea
r 
of
 li
fe
 
C
a=
25
8;
 C
o=
97
 
O
R
(h
t)
=
0.
23
  
[1
25
] 
S
F
T
P
A
2 
rs
19
65
70
8 
U
S 
10
 
C
G
 
O
M
 in
 fi
rs
t y
ea
r 
of
 li
fe
 
C
a=
25
8;
 C
o=
97
 
O
R
(h
t)
=
0.
23
  
[1
25
] 
S
F
T
P
D
 
rs
10
51
24
6 
U
S 
10
 
C
G
 
R
A
O
M
/C
O
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3. Aims of the Study 
The aims of this study were the following: 
To estimate the variance of phenotypic variation in OM that is due to genetic variation in 
Finland (I). 
To evaluate the contribution of genetic variants in innate immunity response genes to OM 
risk in Finnish children (III). 
To assess whether there is a difference in the functionality of TLR4 among subjects with a 
history of OM who have different TLR4 genotypes (III). 
To test if associated TLR4 variants in Finnish study subjects with OM can be replicated in 
other international cohorts (III). 
To find novel genetic variants that contribute to the risk of childhood OM through a GWA 
study (IV) 
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4. Materials and Methods 
4.1. Study subjects and samples 
4.1.1 HUH 
The cohort (hereafter ‘index cohort’) for the studies was collected at the HUH, Department 
of Otorhinolaryngology between 2007-2011. The index patients (probands) came to HUH 
for surgery due to RAOM and/or COME and were recruited along with their parents and 
siblings. Only families with a Finnish ancestry were recruited. All study subjects, or their 
guardians, filled out a questionnaire concerning their middle ear infections and other 
medical conditions including asthma and other atopic diseases, as well as daycare 
attendance, use of pacifiers and other relevant information (Table 3). Altogether, 3009 study 
participants were recruited, of which 1573 were children (701 affected probands, 872 
siblings), 725 mothers, and 711 fathers. Of the recruited patients, DNA samples were 
available for 1931 (813 children, 1118 parents). A second questionnaire was added during the 
patient recruitment period, to include known risk factors for OM (Appendix A-Appendix D). 
Some missing data, such as intraoperative findings, were also acquired from patient records. 
Study subjects, or their guardians, gave written consent to participate. A compilation of the 
patient data from the index cohort is presented in Appendix E. Subsets of the index cohort 
were used in the heritability estimates (I), the candidate gene study (III), and in the GWA 
study (IV). The study was conducted according to the Declaration of Helsinki [155] ethical 
principles for medical research involving human subjects, and the Ethics Committee at the 
HUH approved the study protocol.  
RAOM was defined as more than three AOMs over six months, or more than four AOMs over 
12 months [156]. The definition for COME was MEE for more than two months. A study 
subject was considered affected if s/he had RAOM, COME, or insertion of tympanostomy 
tubes. For the heritability estimates (I), a subset of 590 families (1279 children and 1157 
parents) was used. Family structures and clinical traits for that subset can be found in Table 
4 and Table 5. As study subjects in the candidate gene study (III), we used 624 unrelated, 
affected children from the index cohort, and the same 624 study subjects were included in 
the GWA study (IV), together with 205 patients from the Finnish replication cohort (Section 
4.1.2).Table 6 contains the patient characteristics for these study subjects. 
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Table 3 Clinical traits evaluated in the questionnaire for the index cohort at HUH. 
Question Answer 
More than 3 AOMs over 6 months or more 
than 4 AOMs over 12 months (RAOM) 
Yes/No/Don’t know 
Fluid in the middle ear for more than 2 
months (COME) 
Yes/No/Don’t know 
Hospitals and outpatient clinics where OM 
has been cared for 
Name of institution(s) 
Asthma Yes/No/Don’t know, Age at diagnosis 
Allergic rhinitis (pollen, animal dust) Yes/No, Which? 
Food allergies (milk, egg, cereal) Yes/No, Which? 
Relative´s OM and other ear conditions Yes/No, Who? What? 
Insertion of tympanostomy tubes Yes/No/Don’t know, Number of insertions, 
Year of first insertion 
Adenoidectomy due to OM Yes/No/Don’t know, Year of adenoidectomy 
Other diseases of the ear (perforation of the 
tympanic membrane, cholesteatoma, other 
ear operations)  
Yes/No/Don’t know, What disease 
Any episodes of AOM Yes/No/Don’t know, Number of episodes, Age 
at first AOM 
Paracentesis Yes/No, Number of paracentesis 
Cleft palate Yes/No 
Diabetes, type I or II Yes/No 
Other medical conditions Yes/No, What condition 
Parental smoking Yes/No, Number of cigarettes a day 
Preterm Yes/No, Gestational age, Birthweight 
Breastfeeding Yes/No, Length of full and partial 
breastfeeding 
Use of pacifier Yes/No/Don’t know, Age at discontinuation 
Daycare attendance Yes/No/Don’t know, Age when started 
daycare, Group size 
Atopic dermatitis Yes/No/Don’t know 
Pneumococcal vaccination Yes/No/Don’t know 
Abbreviations: AOM = acute otitis media, COME = chronic otitis media with effusion, OM = otitis media 
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Table 4 Description of family structures used in the heritability estimations (I). 
  N families N children 
Mother, father and 1 child 152 152 
 2 children 255 510 
 3 children 108 324 
 4 children 41 164 
 5 children 11 55 
 6 children 1 6 
 7 children 3 21 
 8 children 1 8 
 13 children 1 13 
Mother and 1 child 9 9 
 2 children 5 10 
 3 children 2 6 
Father and 1 child 1 1 
Total N  590 1279 
Table 5 Clinical data of the family cohort used for the estimation of heritability (I). 
 Parents Children 
 Na Frequency % 
(N) 
Na Frequency % (N) 
COME 743 8.5 (63) 1092 45.4 (496)  
RAOM 820 24.5 (201) 1148 61 (700) 
Any AOM (≥5) 710 18.9 (134) 498 33.7 (168) 
Any AOM (<5) 710 37.6 (267) 498 46.2 (230) 
Male sex 1157 49.5 (573) 1279 55.7 (712) 
Other ear conditionsb 890 7.4 (66) 1147 10.3 (118) 
Adenoidectomy 900 26.0 (234) 1176 44.9 (528) 
Tympanostomy tubes 916 10.4 (95) 1196 59.2 (708) 
Paracentesis 637 14.5 (168) 526 2.3 (30) 
Paternal smoking   788 31.6 (249) 
Maternal smoking   1011 23.5 (238) 
Cleft palate 907 0 1135 0.3 (3) 
Diabetes, type I or II 906 1.9 (17) 1138 0.2 (2) 
Other medical 
conditionsc 
905 12.2 (110) 1143 9.1 (104) 
a Number of patients that answered the question 
b Including hearing impairment, perforation of the tympanic membrane, cholesteatoma, chronic otorrhea and 
other ear operations 
c Including hypertension, ventricular septal defect, atopic eczema, psoriasis, multiple sclerosis, rheumatoid 
arthritis, migraine, hypothyroidism, epilepsy, Crohn’s disease, ulcerative colitis 
Abbreviations: AOM = acute otitis media, COME = chronic otitis media with effusion, N = number, 
RAOM = recurrent acute otitis media 
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Table 6 Clinical data on patient cohorts for the candidate gene study (III) and GWA study (IV). 
Cohort Helsinki 
OM cohort 
Tympanostomy vs 
tympanostomy + 
adenoidectomy cohort 
Total 
 N = 624 N = 205 N = 829 
  N % N % N % 
Male sex 373 60 110 54 483 58 
COME 422 68 102 50 524 63 
RAOM 536 86 185 90 721 87 
Adenoidectomy 407 65 103 50 510 62 
Tympanostomy tubes 567 91 205 100 772 93 
Multiple tympanostomy tubes 196 31 53 26 249 30 
Abbreviations: COME = chronic otitis media with effusion, N = number, OM = otitis media, RAOM = recurrent 
acute otitis media 
4.1.2 Finnish replication cohort 
The independent Finnish replication cohort consisted of children with RAOM that had been 
previously recruited to a study comparing tympanostomy alone versus tympanostomy with 
adenoidectomy in the treatment of RAOM [157] (Table 6). RAOM criteria were the same as 
in the index cohort. Parents gave written consent for the eligible child to participate, DNA 
was available for 205 children. The study was approved by the Ethical Review Committee of 
the HUH. The patients in the Finnish replication cohort were used in the candidate gene 
study (III) to verify the initial results, and in the discovery GWA study (IV). 
4.1.3 International replication cohorts 
UK 
The UK cohort was recruited between April 2009 and November 2013 among British 
children, together with their families, who had insertion of tympanostomy tubes, mainly due 
to COME. The UK cohort was approximately 94% of Caucasian origin. COME was defined 
as MEE for ≥ 3 months and the criteria for RAOM was the same as in the Finnish cohorts. 
1269 trios were included in the replication studies, with 1466 affected cases (proband 
children or their affected sibling) and 3394 subjects with unknown OM history (parents and 
siblings) serving as controls. The study was approved by the NHS Oxfordshire Research 
Ethics Committee. Written informed consent was obtained from the study subjects, or their 
guardians. The UK cohort was used as a replication cohort both in the candidate gene study 
(III) and the GWA study (IV). 
Oregon 
The Oregon (USA) replication cohort included 100 Caucasian patients with COME, defined 
as MEE for ≥ 3 months. They were aged 18 months to 18 years and all had tympanostomy 
tube insertions. Controls included 104 Caucasian patients (18 months to 18 years old) from 
the Oregon otolaryngology clinic that were seen for a nonotologic, nonadenotonsillar 
condition, without a history of any other chronic infection or other inflammatory indication 
[119]. The Oregon Health and Science University Institutional Review Board gave their 
approval for the study. The children’s guardians signed a written informed consent. The 
cohort was used as a replication cohort in the candidate gene study (III). 
Pennsylvania 
The Pennsylvania (USA) replication cohort consisted of 439 families (approximately 95% 
Caucasian) with 1563 (59.1% affected) individuals available for genotyping [150]. A patient 
was considered affected if s/he had insertion of tympanostomy tubes due to RAOM and/or 
COME. The University of Pittsburgh Institutional Review Board granted approval for the 
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study. The children’s guardians gave written informed consent. This cohort was used as a 
replication cohort in the candidate gene study (III). 
4.1.4 Finnish control samples 
As controls for the candidate gene study and the GWA validation study, we used 778 Finnish 
DNA samples that were a subset of samples collected by the Finnish Red Cross in 1998-1999. 
The donors were male, 40-55 years old at the time of donation, and each donor had all four 
grandparents born in the same province of Finland. Collection of the cohort was approved 
by the ethics committee of the Finnish Red Cross and informed consent was given by the 
donors. No clinical information, including OM, was available for the anonymous donors.  
Previously genotyped adults (> 30 years) from the Finnish Health 2000 study were used as 
controls for the discovery GWA study. They were from all parts of Finland and had been 
genotyped on the Illumina Infinium HD Human610-Quad BeadChip (Illimina, San Diego, 
CA, USA) [158, 159]. OM history was not available for these study subjects. 
4.2. Methods 
4.2.1 Heritability estimation 
We estimated the narrow-sense heritability (h2), the ratio of variance of additive genetic 
effects (σ2A) and the observed phenotype (σ2P) (h2 = σ2A/ σ2P), for the genetic component of 
OM. We used SOLAR software, version 4.2.7, which utilizes a variance-component linkage 
method that can be used for pedigrees of different size and complexity [160]. A number of 
potential covariates (age, sex, parental smoking, asthma, milk allergy, egg allergy, cereal 
allergy, allergic rhinitis, animal dust allergy) that may be contributing to the phenotypic 
variance were screened, input as binary covariates in the heritability estimates. At the time 
of the Solar analysis, we only had data available from the original questionnaires (Appendix 
A, Appendix B), therefore breastfeeding, use of pacifier, and information about daycare 
attendance were not taken into account. The best model was achieved when only age and sex 
were used as covariates. 
4.2.2 DNA extraction 
DNA extraction in the index cohort was from peripheral blood using the FlexiGene DNA Kit 
(Qiagen, Hilden, Germany). In the Finnish replication cohort, DNA was extracted from 
peripheral blood samples using the Gentra Puregene Blood Kit (Qiagen, Valencia, CA, USA). 
In the UK cohort, DNA was extracted from saliva samples using an automated system (LGC 
Genomics, Hoddeson, UK). In the Oregon cohort, DNA was extracted from saliva with the 
Oragene DNA Self-Collection Kit (DNA Genotek Inc., Kanata, Ontario, Canada). In the 
Pennsylvania cohort, the Gentra PureGene method (Qiagen, Valencia, CA, USA) was used to 
extract DNA from peripheral blood samples. DNA from the Finnish anonymous blood 
donors had been extracted from blood prior to the present study. 
4.2.3 Genetic association  
Marker selection 
For the candidate gene study (III), polymorphisms were selected based on OM association 
in other cohorts and populations (Section 2.3.3) or polymorphisms associated with asthma 
and allergy in previous GWA studies (Appendix F). The selection of the latter variants was 
based on a hypothesis that there might be common risk variants for atopic diseases (asthma, 
food allergy, allergic rhinitis, and atopic dermatitis) and OM, since there is a clinical 
association between atopic diseases and OM [161, 162].  
To further study the novel association (with TLR4), we selected 16 tagging SNPs from the 
TLR4 region using Haploview 4.2 [163] from a 140 kB locus which includes the TLR4 gene, 
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as well as 97 kB upstream and 32 kB downstream. Only SNPs with MAF > 15% in the CEU 
population, and r2 < 0.8, were selected. Additionally, six other markers were selected, two 
rare coding markers (rs4986790 and rs4986791) that have been extensively studied [164], 
and four that have been previously associated with OM [154]. In the end, the follow-up study 
contained 20 markers, when two markers failed the assay design. After genotyping, one 
marker was excluded due to a low call rate (< 90%) (Appendix G).  
KASP was used for the replication study of the TLR4 variants in the UK and Oregon cohorts 
(III) (rs1329060, rs1329057, rs5030717). TaqMan was used for the replication of the three 
associated TLR4 variants in the Finnish replication cohort (III) and in the Pennsylvania 
cohort (III) (rs1329060, rs1329057, rs5030717; assay ID C___8788422_10, 
C___8788433_10, C__31784023_10). 
To follow up the top results in the discovery GWA study (IV), 30 SNPs were genotyped on 
Sequenom. TaqMan was used for validation of the GWA study results for those markers that 
failed assay design or genotyping on Sequenom (IV) (rs4150992, rs16974263, rs268662; 
assay ID C__30608050_10, C__33845609_10, C___2928476_10). KASP was used for the 
GWA replication study in the UK cohort (IV) (rs16974263, rs4150992). 
Genotyping methods 
Genetic association was assessed with different methods in the studies. The choice was based 
on study design and the number of polymorphisms studied. 
For assessing a few polymorphisms, TaqMan SNP Genotyping Assays (Life Technologies, 
Thermo Fisher Scientific Inc., Waltham, Ma, USA) or KASP primer extension sequencing by 
LGC Genomics (LGC Limited, Teddington, Middlesex, UK) were used. 
Genotyping for the candidate gene study, in the TLR4 tagging analysis, and for the GWA 
follow-up study, MassARRAY Platform from Sequenom (San Diego, USA), was performed 
at the MAF genotyping facility at Karolinska Institutet (Huddinge, Sweden) or by the 
Institute for Molecular Medicine Finland FIMM Technology Centre, University of Helsinki. 
For the GWA study, 826 affected, unrelated Finnish children from the index cohort and the 
replication cohort were genotyped on the Illumina Human OmniExpressExome array-8v1-
2_A at the SNPSEQ Technology Platform in Uppsala, Sweden. The Illumina Infinium assay 
was used for genotyping and GenomeStudio 2000.1 from Illumina was used for the analysis 
of the 964,193 genotyped markers. 
Statistical analysis 
In the case-control cohorts, ORs were calculated and two-tailed Fisher´s exact tests were 
used to estimate p-values for the association results (III, IV). Transmission disequilibrium 
(TDT test) was assessed by PLINK 1.07 (pngu.mgh.harvard.edu/purcell/plink) [165] for the 
UK trios (III, IV). In the Pennsylvanian families, Unphased 3.1.7 was used to test association 
[166] (III). P < 0.05 was considered significant. 
Allelic association of OM with the polymorphisms in the Sequenom studies was assessed 
with PLINK 1.07 (III, IV). There was no significant (p < 0.05) deviation from Hardy-
Weinberg equilibrium (HWE) in controls. ORs were calculated and Fisher’s exact test was 
assessed for statistical significance; p < 0.05 was considered significant. The significance of 
the association was also tested using permutation correction of 10,000 in Haploview (III). 
Power calculations (III) were performed using the Genetic Power Calculator 
(pngu.mgh.harvard.edu/~purcell/gpc), assuming a prevalence of 10% for affected cases 
(RAOM, COME, or insertion of tympanostomy tubes), OR 1.33, and p < 0.05 [146]. 
In the GWA study (IV), markers with low call rates (< 95%), samples with low call rates 
(< 99%), markers with discordance in duplicates, and markers showing control genotypes 
inconsistent with previous genotype results, were removed. Genotype data from cases and 
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controls were combined, and only markers that were in both sets were used in the final 
analysis. Markers with HWE p-values < 0.0001 in controls, markers with MAF < 5%, and 
markers with highly different allele frequencies in cases and controls (e.g. 0% versus 100% 
for the same allele) were removed. 
In the GWA study (IV), allelic association was assessed for all affected cases, COME, and 
RAOM, with PLINK 1.09 using Fisher’s exact tests. ORs, 95% CIs, uncorrected p-values, and 
corrected p-values were calculated. P-value correction was assessed with the PLINK function 
“- - adjust” which generates significance values for Genomic control, Bonferroni, Holm step-
down, Sidak single-step, Sidak step-down, Benjamini & Hochberg, and Benjamini & 
Yekutieli correction. The genomic inflation factor, λ, was calculated with PLINK. λ is defined 
as the ratio of the median of the empirically observed distribution of the test statistic to the 
expected median, quantifying the extent of the bulk inflation and the excess false-positive 
rate. With quantile-quantile (Q-Q) plots, deviations of the observed distribution from the 
expected null distribution can be visualized [167]. Q-Q plots and Manhattan plots, for 
visualization of the association results along the genome, were generated using the R 
package “qqman”. An uncorrected p-value < 5 x 10-8 was considered significant, as it is a 
threshold for genome-wide significance. Logistic regression with sex as a covariate was also 
performed using PLINK. Power was calculated (IV) using the Genetic Association Study 
Power Calculator (csg.sph.umich.edu/abecasis/CaTS/gas_power_calculator) [168]. 
Table 7 Study subjects for the assessment of TNFα protein expression and TNFα mRNA expression. 
20 Finnish age- and sex-matched patients with RAOM and/or COME.  
Patient Sex Age Genotype for the TLR4 haplotype 
1 M 13 Heterozygote 
2 M 13 CTA 
3 F 12 Heterozygote 
4 F 12 CTA 
5 M 12 Heterozygote 
6 M 12 CTA 
7 M 14 Heterozygote 
8 M 14 CTA 
9 M 13 TCG 
10 M 13 Heterozygote 
11 M 11 TCG 
12 M 13 CTA 
13 M 10 TCG 
14 M 13 CTA 
15 F 23 TCG 
16 F 33 CTA 
17 M 10 TCG 
18 M 12 CTA 
19 F 10 TCG 
20 F 10 Heterozygote 
Abbreviations: F = Female, M = Male 
4.2.4 Flow cytometry and mRNA analyses 
Twenty patients from the Finnish index cohort were recruited for studies on TNFα protein 
and mRNA expression. TNFα is a downstream cytokine of TLR4 (Figure 11) and was used 
because our attempts on studying TLR4 expression did not succeed. Ten age- and sex-
matched pairs (Table 7), one carrying the risk haplotype (TCG), the other being homozygous 
for either the risk (TCG) or protective (CTA) haplotype, gave fresh peripheral blood samples, 
and these paired samples were analyzed in parallel.  
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For the FACS (fluorescence-activated cell-sorting flow cytometry) analysis, fresh 
heparinized blood was stimulated with the TLR4 ligand LPS (1 μg/ml, Sigma-Aldrich, NY) 
for a total of 5 hours. Monensin (BD GolgiStop, BD Biosciences, CA) was added after 1 hours 
of stimulation. Cells were stained with fluorescence conjugated antibodies against CD14 (PE-
Cy5.5, Invitrogen, MHCD1418), CD1c (APC, Miltenyi, 130-090-903), CD11c (PE, BD 
Biosciences, 333149), and CD19 (PE-Cy5.5, Invitrogen, MHCD1918). Red blood cells were 
lysed using FACS lysing solution (BD Biosciences, 349202). After centrifugation (500 g for 
5 min) and washing (5% FBS+0.02% NaN3 in PBS), the cells were permeabilized with 
Cytofix/Cytoperm Plus Fixation and Permeabilization Kit (BD Biosciences, 555028). The 
cells were then stained either with anti-TNFα PE antibody (BD Pharmingen, 554513) or an 
isotype control (mouse IgG1, BD Pharmingen, 554680). Unbound antibodies were washed, 
cells were re-suspended in paraformaldehyde (1%), stored at +4°C, and analyzed with a 
FACSCalibur flow cytometer (BD Biosciences) the following day. FACS results were analyzed 
with FlowJo 7.6.1 and GraphPad Prism 6.  
For mRNA expression studies, peripheral blood mononuclear cells were isolated from 
heparin-anticoagulated blood using density centrifugation (Ficoll-Paque, Amersham 
Biosciences, Uppsala, Sweden). Isolated mononuclear cells were suspended in cell culture 
media consisting of RPMI 1640 (Gibco, ref. 42401) supplemented with 5% heat-inactivated 
human AB-serum (Innovative Research), 2 mmol/l L-glutamine (Gibco), and 25 μg/ml 
Gentamicin (Sigma). The cells were frozen in the above media supplemented with 10% 
DMSO (Sigma, D2650) at 3 to 5 million cells/ml. After thawing, peripheral blood 
mononuclear cells were stimulated in the above cell culture media with or without LPS 
(1 μg/ml, Sigma) for 4 hours. Total RNA was isolated with Qiagen RNeasy Mini kit (Qiagen, 
Hilden, Germany) and cDNA (complementary DNA) was synthesized using the High 
Capacity cDNA Reverse Transcription kit (Applied Biosystems, Foster City, CA, USA). Gene 
expression levels were analyzed with real-time quantitative polymerase chain reaction 
(qPCR) using the TaqMan Gene Expression assay that is specific for TNFα 
(Hs00174128_m1). The qPCR runs were performed in triplicates and qPCR for the 
ribosomal 18s subunit (Hs03928985_g1) was used as an endogenous control for 
normalization of the amount of RNA. We used a control RNA sample prepared from 
phytohaemagglutinin-stimulated human peripheral blood mononuclear cells to control for 
inter-assay variation. 
The Mann-Whitney U-test was used to test the differences in protein and mRNA expression 
between the genotypes in the functional studies; p < 0.05 was considered significant. 
4.2.5 In Silico Analysis 
To elucidate the biological function of the discovered genetic associations and why they 
might alter the risk for OM, we investigated publicly available databases (see section 2.2.5) 
on previously gathered information about the genes, variants, and loci. 
The candidate genes’ expression, TSSs and transcripts were investigated through FANTOM5 
(fantom.gsc.riken.jp/zenbu), a public database which focuses on systematically investigating 
transcriptional expression in virtually all cell types across the human body. They aim to use 
the information to build transcriptional regulatory models for every primary cell type that 
makes up a human [169].  
The GTEx Portal (www.gtextportal.org) was used to search potential expression quantitative 
trait loci (eQTL) that contribute to variation in the expression levels of mRNA in various 
tissues [87].  
The UCSC Genome Browser (ENCODE data) was used to investigate the associated genetic 
variants [170], and the Human Protein Atlas was used to examine RNA and protein 
expression [88]. GRASP (Genome-Wide Repository of Associations Between SNPs and 
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Phenotypes) was used to investigate whether our new findings had previously been 
associated with other phenotypes in other studies [89].  
The ToppGene portal (toppgene.cchmc.org) analyzes information from a number of sources, 
such as information on gene ontology categories (which functional categories and pathways 
a set of genes fall into), phenotypes and diseases, pathways, previous publications, and 
known interactions. Each of the candidate genes is given a score based on their similarity to 
the genes in the training dataset, and an overall p-value. The ToppGene portal was used to 
rank the suggested candidate genes in our GWA study by evaluating them against a training 
dataset based on the previously described candidate genes (Table 2) [171]. 
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5. Results 
5.1. Heritability (I) 
Heritability was estimated from the index cohort data gathered until the end of 2009, using 
the Solar software. At that time, the cohort included 590 families (Table 4) totaling 2436 
study subjects: 1279 children (712 (55.7%) male), 584 mothers, and 573 fathers. The reported 
incidence of RAOM (61% vs 24.5%), COME (45.4% vs. 8.5%), insertion of tympanostomy 
tubes (44.9% vs. 26%), and adenoidectomy (59.2% vs. 10.4%) was higher among children 
compared to parents, respectively. Paracentesis, on the other hand, had been performed 
more frequently among the parents (14.5% vs 2.3%), reflecting a change in the treatment of 
OM. The largest family had 13 children, although the most typical family unit consisted of a 
mother, a father, and two children. Age and sex were used as covariates in the heritability 
estimations. The h2 for RAOM, COME, and all episodes of OM was 0.39 (p = 7.3x10-9), 0.22 
(p = 4.6x10-3), and 0.48 (p = 1.5x10-11), respectively (Table 8). 
Table 8 Heritability estimates for OM. 
Trait h2 Age Sex R2 e2 p value 
RAOM 0.39 + + 0.13 0.61 7.3 x 10-9 
COME 0.22 + + 0.15 0.78 4.6 x 10-3 
Any OM 0.48 +  0.14 0.52 1.5 x 10-11 
Note: Significant covariates are marked with + 
Abbreviations: COME = Chronic otitis media with effusion, h2 = Heritability estimate for trait, after accounting 
for effect of covariates, OM = Otitis media, R2 = Kullback–Leibler value, an estimate to indicate the effect size of 
the covariates in the model, RAOM = Recurrent acute otitis media, e2 = proportion of variance explained by 
environmental (non-genetic) effects. 
5.2. Candidate gene study (III) 
After assay design at the MAF genotyping facility, genetic polymorphisms were assessed for 
53 SNPs on 35 different genes for 624 unrelated children from the index cohort and 778 
controls (Appendix F). Six markers failed genotyping and three markers were monomorphic; 
thus, 44 markers, of which 36 were independent, were analyzed. Only one polymorphism, 
rs5030717, in the gene TLR4 was significantly associated with OM (OR 1.33, p = 0.003). The 
risk polymorphism is located in the third intron of TLR4, the G-allele being more common 
in affected patients. The association remained when looking specifically at RAOM and 
COME (OR 1.33, p = 0.005; OR 1.34, p = 0.007, respectively) and was even stronger in the 
more severe phenotypes of children with multiple insertions of tympanostomy tubes and 
those with their first AOM before the age of six months (OR 1.68, p = 0.0008; OR 2.05, 
p = 0.009, respectively) (Table 9). In the subsequent tagging gene approach (see section 
2.2.1) for the TLR4 region (Appendix G), we detected two additional polymorphisms that 
were associated with OM, rs1329060 and rs1329057 (Table 9). The three markers define a 
risk haplotype, since they are in strong LD (Figure 3 ). Four other markers in the TLR4 region 
were also suggestive of association with OM (puncorr < 0.05), these might be part of the same 
TLR4 association, isolated findings in the TLR4 region, or false-positive findings (Type I 
error). 
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Table 9 Association analysis in the Finnish index cohort of 624 children with RAOM and/or COME 
with the markers rs5030717, s1329060, and rs1329057 in the TLR4 region. 
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All affected OM1 rs1329060 T 0.28 0.23 1.33 1.11 - 1.58 0.00157 * 
N = 624 rs1329057 C 0.31 0.26 1.29 1.09 - 1.53 0.00296 * 
 rs5030717 G 0.23 0.18 1.33 1.10 - 1.61 0.00329  
RAOM rs1329060 T 0.29 0.23 1.33 1.11 - 1.59 0.00227 * 
N = 422 rs1329057 C 0.31 0.26 1.29 1.08 - 1.54 0.00437  
 rs5030717 G 0.23 0.18 1.33 1.09 - 1.61 0.00478 * 
COME  rs1329060 T 0.29 0.23 1.37 1.13 - 1.66 0.00160 * 
N = 536 rs1329057 C 0.33 0.26 1.36 1.13 - 1.64 0.00115 * 
 rs5030717 G 0.23 0.18 1.34 1.09 - 1.66 0.00655  
Multiple 
insertions of 
tympanostomy 
tubes 2 N = 203 
rs1329060 T 0.33 0.23 1.65 1.30 - 2.11 0.00004 * 
rs1329057 C 0.37 0.26 1.62 1.28 - 2.04 0.00006 * 
rs5030717 G 0.27 0.18 1.68 1.30 - 2.18 0.00008 * 
Early onset AOM 3 rs1329060 T 0.42 0.23 2.42 1.45 - 4.04 0.00048 * 
N = 32 rs1329057 C 0.44 0.26 2.19 1.32 - 3.63 0.00201 * 
 rs5030717 G 0.31 0.18 2.05 1.19 - 3.54 0.00860  
Note: Genotyping performed on Sequenom. 
*Significant (p < 0.05) after permutation correction of 10000  
1 All OM = RAOM, COME, or insertion of tympanostomy tubes  
2 insertions of tympanostomy tubes ≥ 2  
3 First AOM before the age of six months  
Abbreviations: AOM = Acute otitis media, A1 = minor allele, CI = Confidence interval, COME = Chronic otitis 
media with effusion, fA = frequency of the minor allele, OM = Otitis media, OR = Odds ratio, RAOM = Recurrent 
acute otitis media, SNP = single nucleotide polymorphism, uncorr = uncorrected 
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Figure 3 LD between markers in the TLR4 tagging gene study in the Finnish index cohort. The 140 
kB locus includes the TLR4 gene, and also 97 kB upstream and 32 kB downstream. Approximate 
position of the TLR4 gene is denoted by the red line, with the arrow indicating the reading direction. 
The green boxed markers comprise the hypothesized risk haplotype. Numbers in squares indicate the 
coefficient of LD, the higher the number the higher the LD. Figure created in Haploview 4.2. 
In the genotyping of the novel TLR4 TCG risk haplotype in a separate Finnish cohort of 205 
children with RAOM, the three markers showed the same manner of association (OR 1.37, 
p = 0.012; OR 1.31, p = 0.027; OR 1.50, p = 0.050) (Table 10). In three international, mainly 
Caucasian, cohorts, the MAFs for the three markers were considerably lower; for the 1269 
trios from the UK, 439 families from Pennsylvania, US, and 100 cases and 104 controls from 
Oregon, US, the association was unable to be confirmed (Table 10). In the US cohorts, there 
was a trend toward the opposite association with rs1329060 (T) (OR 0.79, p = 0.05; 
OR 0.53, p = 0.059; for Pennsylvania and Oregon, respectively). The alternative haplotype, 
CTA, showed the opposite association in the Pennsylvania cohort (OR 1.35, p = 0.001), 
compared to the Finnish index study (OR 0.69, p = 0.003). 
The index cohort had an estimated power of 76% to identify variants with a frequency of 
23%, whereas the combined Finnish cohorts had 82%, the UK cohort 90%, the Pennsylvania 
cohort 47%, and the Oregon cohort 17% power (assuming an affected prevalence of 10% and 
OR 1.33). 
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Table 10 Replication analysis of SNPs in the TLR4 region in an independent Finnish cohort, in a UK 
cohort, and in two US cohorts.  
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Finnish 
replication 
cohort * 
205 778        
  rs1329060 T 0.289 0.228 1.37 1.06–1.75 .012 
  rs1329057 C 0.317 0.259 1.31 1.04–1.67 .027 
   rs5030717 G 0.223 0.179 1.50 1.02–1.74 .050 
Oregon, US+ 100 104        
   rs1329060 T 0.085 0.148 0.53 0.28-1.04 .059 
   rs1329057 C 0.125 0.185 0.63 0.35-1.32 .113 
   rs5030717 G 0.061 0.099 0.59 0.27-1.28 .179 
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UK+ 1269        
   rs1329060 T 273 274 1.00 0.84-1.17 .966 
   rs1329057 C 347 349 0.99 0.86-1.15 .940 
   rs5030717 G 222 214 1.04 0.86-1.25 .702 
Pennsylvania,
US* 
439         
  rs1329060 T 136 182 0.79 0.62-1.00 .050 
  rs1329057 C 168 212 0.85 0.69-1.06 .158 
  rs5030717 G 118 141 0.94 0.72-1.22 .654 
* = genotyping on TaqMan  
+ = genotyping on KASP  
Abbreviations: A1 = minor allele, CI = Confidence interval, fA = frequency of the minor allele, N = Number, 
OR = odds ratio, SNP = single nucleotide polymorphism, Trans/Untrans = transmitted/untransmitted allele in 
the TDT-test, US = United States, UK = United Kingdom 
In eQTL analyses, the minor allele of TLR4 markers that are in LD with our risk haplotype 
have lower expression of TLR4 (Figure 4). We did mRNA and protein expression studies 
based on peripheral blood taken from patients with or without the TCG TLR4 risk haplotype. 
Quantification of TLR4 protein by FACS proved to be difficult due to low cell surface 
expression. Quantification of TLR4 mRNA was also difficult because of multiple different 
TLR4 mRNA transcripts due to several different splicing variants and multiple different 
mRNA TSSs. Therefore, we stimulated cells with the TLR4 ligand LPS and measured the 
downstream cytokine TNFα to model the function of TLR4 transcribed by the risk haplotype. 
The relative expression of TNFα mRNA was higher in those with the risk haplotype when 
peripheral blood mononuclear cells (PBMC) were stimulated with LPS, compared to those 
without the risk haplotype (Figure 5).  
FACS analysis of myeloid DCs stimulated with LPS showed that carriers of the TLR4 TCG 
risk haplotype had lower expression of TNFα, compared to non-carriers (p < 0.01) (Figure 
6). 
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Figure 4 eQTL of rs2770146 (Ref allele = T, Alt allele = C) in whole blood and rs1329057 (Ref 
allele = C, Alt allele = T) in left heart ventricle. Those with the alternative allele, which was in LD with 
the novel TLR4 risk haplotype, have lower expression of TLR4. The figure is an image capture from the 
GTEx portal (gtexportal.org) on 04/09/2016. 
 
Figure 5 The relative mRNA expression of 
TNFα in PBMC of affected children with the 
TCG risk haplotype of TLR4 was compared 
with the protective CTA haplotype. The Mann-
Whitney U-test was used for statistical 
assessment. Boxes show the interquartile 
range (25-75%), where the horizontal bar 
shows the median, and the whiskers indicate 
the minimum and maximum values; 
o = outlier. 
 
Figure 6 The relative expression of TNFα in 
myeloid dendritic cells (mDCs) in affected 
children with the TCG risk haplotype of TLR4 
was compared to children with the protective 
CTA haplotype. The Mann-Whitney U-test was 
used to test the difference between the groups. 
5.3. GWA study (IV) 
5.3.1 Association analysis 
The GWA analysis was based on 319,683 markers from 803 Finnish otitis-prone cases and 
2073 controls after quality control (Table 6). All subjects had a call rate > 95%, and the 
genotyping rate was 99.9%. Figure 8 shows the Q-Q plot for the associations. The genomic 
inflation factor for affected cases and controls was λaffected = 1.028, λCOME = 1.0121, 
λRAOM = 1.029. The Q-Q plot and the genomic inflation factor indicate that there is no hidden 
stratification between cases and controls. Genotyping the cases and controls on different 
arrays carries a potential risk for errors. Therefore, we performed a validation of the initial 
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results by re-genotyping the top SNPs for the cases and a different set of 778 controls on 
TaqMan or Sequenom.  
The association results are depicted in the Manhattan plot in Figure 7 for all OM, RAOM, 
and COME. A classical “tower” in the Manhattan plot was found on chromosome 19, 
comprising four SNPs (Figure 10 C). Four markers, one on chromosome 2, 6, 21 and X, had 
a p-value < 10-10, but these associations could not be replicated using another genotyping 
platform, suggesting that these associations were false positives (Table 11A&B). Also, the 
concordance of the genotypes in the GWA study versus when genotyped on Sequenom or 
TaqMan was lower in these markers, indicating that the association with these markers in 
the initial GWA study was likely to be an artifact, caused by unknown genotyping errors or 
differences in assay design.  
The four risk SNPs that were more common among those affected were allele A of 
rs16974263 (OR 1.59, p = 1.76x10-7), allele C of rs268662 (OR 1.53, p = 1.5x10-6), allele G of 
rs4150992 (OR 1.52, p = 3.37x10-6), and allele A of rs4803329 (OR 1.44, p = 9.63x10-5) 
(Figure 9). Allele A of rs16974263 was still significant after Benjamini-Hochberg false-
discovery rate correction (p = 0.011), but not for Bonferroni correction (p = 0.057). Adding 
sex as a covariate in the GWA analysis yielded very similar association results and was not 
followed up further. In the subgroup of patients with COME, the association was stronger 
for all markers (Figure 9) and achieved genome-wide significance (p < 5x10-8), with two 
markers remaining significant even after the strict Bonferroni correction (prs16974263 = 0.009; 
prs268662 = 0.021). The subphenotype analyses of RAOM gave results similar to those for all 
affected. Three of the four associated markers were successfully genotyped with similar 
results on a different platform to validate the findings. The same patients as those in the 
initial GWA study as well as the 778 blood donor controls were used in the validation (Table 
11B). In the validation study, all genotyped markers were in HWE (p > 0.05) among controls. 
The study had 83% power to detect a variant with 20% frequency at the genome-wide 
significance level of p = 5x10-8, but only 27% to detect a variant with 10% frequency, 
assuming 10% prevalence of RAOM/COME and RR = 1.5.In a UK cohort of mainly COME-
prone families, we assessed two of the four associated markers (rs16974263 and rs4150992). 
The genotyping was successful in 1247 full trios; the markers were significantly associated, 
but in the opposite direction (OR 0.71, p = 0.00032; OR 0.71, p = 0.00016) (Table 11C). 
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Figure 7 Manhattan plots for 
the associations of all affected 
OM, COME, or RAOM with 
each chromosome. Each dot 
represents one SNP, the 
approximate position of each 
marker on chromosome 1 to X 
is depicted on the x-axis; on 
the y-axis is the -log10(p) 
value. Higher y-values 
indicate a more significant 
association. The red line at -
log10(p) = 7.3 indicates the 
threshold for fully genome-
wide significant association, 
and the blue line at 5 indicates 
a suggestive association. 
* =  Outliers on chromosomes 
2, 6, 21 and X, -log10(p) 
values not shown. Figure by 
Elisabet Einarsdottir. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8 Q-Q plot for all genotyped cases 
and controls in the discovery GWA study. 
Observed - log10(p-value) on the y-axis, and 
expected -log10(p-value) on the x-axis. Figure 
created by Elisabet Einarsdottir using the R 
package “qqman”. 
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5.3.2 In Silico Analysis 
The four associated markers lie within a 80 kb LD block on chromosome 19 (Figure 10 A, B), 
probably reflecting one association signal. The region contains the genes Biliverdin 
reductase B (BLVRB), Homeodomain-interacting protein kinase 4 (HIPK4), Phospholipase 
D family, member 3 (PLD3), Periaxin (PRX), and Serta domain-containing 1 and 3 
(SERTAD1, SERTAD3). Part of the exon and promoter region of BLVRB and PLD3 are not 
covered by the LD block.  
None of the four markers have previous associations (p < 1x10-4) with other trait according 
to GRASP. From the FANTOM5 data, we found three strong TSSs in our novel risk locus, 
one in the coding region of the SERTAD1 gene, one in the 5’ UTR of the SERTAD3 gene, and 
one in the middle of the PLD3 gene. In the Human Protein Atlas, we found that PRX protein 
is expressed in the kidneys and peripheral nerves, BLVRB protein is expressed in almost all 
tissues, and PLD3 is also expressed in all tissues, especially in neuronal tissue in the brain, 
the white pulp of the spleen, the macrophages in the lung, and in the epididymis. No data 
was available for SERTAD1, SERTAD3, and HIPK4 protein expression. In ENCODE, we 
found functional elements in the region of the six genes; seven probable strong expression 
start sides, 11 likely CpG islands, and dozens of likely transcription factor binding sites that 
might alter the expression of the genes. The ToppGene analysis generated the average rank 
for the genes in the region; PLD3 (0.53, p = 0.03), SERTAD1 (0.50, p = 0.04), BLVRB (0.47, 
p = 0.04), PRX (0.38, p = 0.06), SERTAD3 (0.40, p = 0.33), and HIPK4 (0.24, p = 0.73). 
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Figure 10 (A) Association with OM in markers within a 200 kb region surrounding rs16974263 and 
their estimated LD with each other. The genes that are located within the region are shown (plotted 
based on data from the hg19/1000 Genomes dataset, Nov 2014 EUR population). (B) Pairwise D´ LD 
between all markers in the region based on our data. The selected markers constitute a block of strong 
LD which contain our markers that are associated with OM. (C) GWA study Manhattan plot for 
chromosome 19 (b37). Figure by Elisabet Einarsdottir. 
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6. Discussion 
We have shown in our large Finnish cohort of patients with childhood OM that there is a 
substantial heritable component of OM in the Finnish population. In our material, the 
previously known candidate gene TLR4 appeared as a strong genetic risk factor for OM in 
the Finnish population. We also found a novel genetic risk locus for OM on chromosome 19 
through a large GWA study. The precise functions of the findings in OM are still not clear, 
but justify further studies in order to better understand the pathogenesis of this common 
disease. 
6.1. Heritability of OM in Finnish population 
In order to carry out the hunt for genetic risk variants of OM, we started by estimating the 
genetic risk component in the recruited cohort. In the analyses of 1279 children, 584 mothers 
and 573 fathers, we estimated the h2 for OM in the Finnish population to be 22-48%. This is 
somewhat lower than in previous twin studies conducted in Norway, Wales, and the US, 
where the h2 has been estimated to be 49-74% [8-10, 93, 94, 172]. There might be several 
reasons for the discrepancy including environmental factors, as well as study design. The 
diagnostic criteria for OM may also vary in populations and over time; therefore, the time 
and place of the enrollment of study subjects with OM affects the study results. The median 
year of birth for the probands in our cohort was 2004, whereas the twin studies were based 
on twins or triplets born in 1967-1979, 1994, and 1982-2000. Patterns in daycare attendance 
have also changed over the course of time, and daycare practices differ between countries. 
Since daycare attendance is a strong risk factor for OM, the fact that at the age of four less 
than 50% of Finnish children attend daycare might influence the results [173]. The Solar 
analyses were done before we had information about daycare attendance, breastfeeding and 
use of pacifiers, and using them as covariates might have altered the results. Parental 
smoking is another risk factor for OM, and in our cohort the proportion of smoking parents 
was higher (24% of mothers and 32% of fathers) than in the Finnish population in general 
(18% among adult females and 24% among adult males) [174]. The design of the study was 
different from previous heritability studies of OM. The selection of our family cohort was 
based on probands with verified COME and/or RAOM, whereas in the twin studies, the 
patients were unselected concerning OM. The possibility of recall bias is also one potential 
weakness in our study, since the data about OM history of the parents were based on the 
recollection of the study subject. Despite the heritability being somewhat smaller in our 
cohort, our analysis indicated a significant heritability of OM in the Finnish population, 
which encouraged us to go further with genetic association analyses. 
6.2. Association of TLR4 to OM 
The innate immunity gene TLR4 has previously been suggested as a candidate gene for OM. 
We were able to replicate the association of TLR4 as a genetic risk locus for OM in the Finnish 
cohort, and found a relatively strong and significant risk haplotype for OM. The association 
was even stronger in those children with the first OM episode before the age of six months 
and with multiple insertions of tympanostomy tubes. TLR4 plays an important role in the 
innate immunity [175] (Figure 11). TLR4 is activated by all the major pathogens of AOM: 
Streptococcus pneumonia [176], Haemophilus influenzae [177], and Moraxella catarrhalis 
[178]. 
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Figure 11 TLR4 signaling pathway. The activation of a TLR4 receptor can lead to the activation of two 
different pathways; the nuclear factor kappa B (NF-κB) pathway activates the transcription of pro-
inflammatory cytokines, while the other, interferon regulatory factor 3 (IRF3) pathway, activates the 
expression of interferon β (INFβ) and other INF genes. The cascade is initiated when a ligand binds to 
the extracellular domain of TLR4 with the help of myeloid differentiation protein-2 (MD-2), LPS-
binding protein (LBP) and CD14. The cytokine cascade is MyD88 dependent, leading to NF-κB 
activation, while the INF pathway leads to IRF3 activation without MyD88. Figure from Noreen et al. 
[175] with permission from Springer International Publishing. 
Impairment of the innate immunity has consequences for susceptibility to infections and 
recovery from infections. The immune system of the newborn child is immature and depends 
upon the congenital maternal antibodies, those acquired during lactation, and the innate 
immunity [179]. The adaptive immunity develops as the child starts to discover its 
environment and evolves throughout life. The function of the innate immunity alters with 
age [180], as does the immune system of the middle ear [181]. TLR4 is located on the surface 
of monocytes, macrophages, DCs, neutrophils, and endothelial cells. Upon recognizing 
ligands, for instance LPS of pathogens, they initiate the inflammatory cascade which 
activates the transcription and expression of cytokines (IFNβ, TNFα, IL-6, IL-8, IL-12) [175]. 
TLR4 is expressed in the MEE and adenoids in patients with COME [120, 182].  
The genetic polymorphisms in the TLR4 gene have been extensively studied in several 
phenotypes. In particular, two missense polymorphisms (rs4986790 (Asp299Gly), 
rs4986791 (Thr399Ile)) in the TLR4 gene that alter the extracellular domain of TLR4 [183] 
have been extensively studied, and associated with several phenotypes including infectious 
diseases, autoimmune diseases, cardiovascular diseases, and even cancer [175, 184]. These 
polymorphisms have an MAF of 4% in Western and Northern European population, 12% in 
the Finnish, as well as the Southeast Asian, populations, but are absent in the Eastern Asian 
populations [83]. In a Dutch cohort of children with OM, one of the markers showed an 
association [115], but in a US cohort the two markers were not associated with OM [117]. 
Other TLR4 SNPs have also been studied. In a US family study, rs2770146 in the TLR4 
region showed nominal association with OM, but the result could not be replicated in 
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another US family cohort [113]. In yet another case-control study in the US on OM, five TLR4 
polymorphisms were suggestive of association (punadjusted = 0.007–0.031, padjusted = 0.63–
0.98) [119].  
The impact of TLR4 on OM has been demonstrated in mouse models. TLR4 -/- mice produce 
significantly lower levels of proinflammatory cytokines, have impaired bacterial clearance in 
their middle ear after Haemophilus influenzae challenge, and have increased bacterial load 
in their lungs after challenge with Moraxella catarrhalis [178, 185]. Furthermore, in mice, 
when TLR4 is activated by monophosphoryl lipid A before Haemophilus influenza and 
Moraxella catarrhalis challenges, bacterial clearance is enhanced [186]. 
The result for the three markers comprising a haplotype was similar in our Finnish 
replication cohort of children with RAOM and/or COME. On the other hand, we were not 
able to replicate our significant findings in two US and one UK cohort. There might be several 
explanations for this, including differences in study setting, different diagnostic criteria, 
genetic variance in populations, as well as environmental factors, or a spurious initial result 
due to a Type I error (see section 0). The same explanations can be applied to explain why 
we could not replicate nine other candidate genes that have previously been suggested to be 
genetic risk factors for OM [95, 104]. 
In order to evaluate the biological characteristics of the TLR4 risk haplotype, we did 
functional studies by stimulating peripheral blood from selected study subjects. Altogether, 
six subjects with the homozygous (TCG) TLR4 risk haplotype, eight with the homozygous 
(AGC) protective haplotype, and six heterozygote subjects were studied. Upon stimulation 
of myeloid dendritic cells with LPS, FACS analysis indicated production of significantly 
lower amounts of TNFα protein in patients with the risk haplotype. We were not able to study 
TNFα mRNA expression in myeloid dendritic cells, but in LPS-stimulated PBMCs, TNFα 
mRNA was up-regulated in the risk haplotype. The GTEx portal reveals that there are TLR4 
variants that have strong eQTL effects on TLR4 mRNA expression. Our discovered variants 
overlap with that region and some variants are in strong LD, therefore we suggest that the 
MAF (TCG) leads to decreased TLR4 expression, leading to OM susceptibility, especially 
RAOM in young children. Two of the associated markers (rs1329060, rs1329057) lie 
upstream from the gene, and one is in an intronic region (rs5030717). The variants might 
alter mRNA expression by affecting the gene enhancers. The reason for the persistence of an 
allele that increases the risk of OM is unknown. One explanation of our finding is that the 
evolutionary conservation of the low response TCG haplotype of TLR4 might have been 
beneficial in order to reduce the inflammatory response during allergy, tissue injury, and 
sepsis [187-189].  
Taken together, the innate immunity is important as the first line of defense for infection 
and also in the clearance in infection and inflammation. Variants in the innate immunity 
gene TLR4 are factors adding to the risk for RAOM and COME in the Finnish population.  
6.3. A new genetic association to OM on chromosome 19 
Our GWA study on 829 otitis-prone children and 2118 controls revealed a new OM risk locus 
on chromosome 19, which harbors the genes PLD3, HIPK4, PRX, SERTAD1, SERTAD3, and 
BLVRB. The risk locus spans ca. 80 kb in strong LD, and therefore we were not able to 
identify the exact variant that might mediate the risk for COME. The GWA setting makes it 
possible to find new genetic markers for a phenotype that would not have been hypothesized 
in other ways. The locus that we identified is unique in that it has not previously been 
associated with the pathogenesis of OM. 
Linkage studies on OM have also previously found association with a region on chromosome 
19 (q13.42-q13-43) [97], but that region does not overlap with our GWA association in the 
19q13.2 region. Two suggested candidate genes for OM, TGFβ [132, 134] and SCN1B [113], 
on chromosome 19 are also not overlapping with our GWA association. Previous GWA 
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studies on OM have implicated associations between OM and regions on chromosomes 2 
and 20 [148-150]. The marker rs10497394 (Chromosome 2) was genotyped in our data, but 
did not show association. This might imply a spurious initial finding that might be due to the 
rather small GWA study on the US cohort (373 affected), having power too low to detect 
significant variants. We did find our previous association between the variants in TLR4 and 
OM, but this association did not reach genome wide significance in this GWA setting. In the 
vicinity of previously suggested risk variants for OM (Table 2), there were only two 
suggestive replications in our GWA data, for CAPN14 (p = 0.0054 [148]) and SMAD2 
(p < 0.05 for three markers [119]). 
The candidate genes PLD3, HIPK4, PRX, SERTAD1, SERTAD3, and BLVRB in the risk locus 
are not self-explanatory as risk genes for OM. The ToppGene analysis, which is based on 
other candidate gene studies on OM, and several databases suggest that BLVRB, PLD3, or 
SERTAD1 may be more likely OM candidate genes than HIPK4, PRX, or SERTAD3. Most of 
the previously suggested candidate genes for OM are from the innate immunity system, 
skewing the ToppGene analysis somewhat. The candidate genes’ expression patterns were 
investigated through FANTOM5, a public database which focuses on systematically 
investigating transcriptional expression in virtually all cell types across the human body, as 
well as in mice [169]. 
BLVRB 
Biliverdin reductase B (BLVRB) is one of the two biliverdin reductase isoenzymes. According 
to FANTOM5, it is expressed in CD34+ cells, as well as in whole blood, monocyte-derived 
macrophages responding to certain influenza infections, and bronchial epithelial cells. 
According to the GTEx portal and Human Protein Atlas, BLVRB RNA and BLVRB protein 
are expressed and found in almost all tissues. The biliverdin reductase enzyme converts 
biliverdin to bilirubin, where biliverdin is a degraded product from heme. Heme is a 
macromolecule in hemoglobin, myoglobin, cytochrome, catalase, heme peroxidase, 
endothelial nitric oxide synthase, and other biologically important hemoproteins. Therefore, 
bilirubin influences many biological events that have cytoprotective, anti-proliferative, anti-
inflammatory, anti-oxidative, anti-apoptotic and anti-tumor effects [190, 191]. It is 
interesting that one of the mechanisms by which biliverdin reductase regulates the 
inflammatory response is by inhibiting TLR4 transcription and protein expression [192, 
193]. 
PLD3 
Phospholipase D family, member 3 (PLD3) catalyzes the hydrolysis of membrane 
phospholipids resulting in the formation of second messengers in the endoplasmic 
reticulum, and might be important for epigenetic modification, anti-apoptosis, and cell 
differentiation [194]. One of the two PLD3 promoters is strongly activated to initiate 
transcription by LPS in monocyte-derived macrophages, which is interesting in the context 
of OM pathogenesis. In the nervous system, it is the glial cells that act similarly to the 
macrophages, as a major component of the neuroinflammatory responses [195]. PLD3 is also 
expressed in the brain, and genetic variants of PLD3 have been associated with the risk of 
late onset Alzheimer’s disease [196].  
SERTAD1, SERTAD3, PRX 
Serta domain-containing 1 (SERTAD1) is a transcription factor with one main promoter. 
This gene is, according to FANTOM5, up-regulated after challenge with influenza virus in 
monocyte-derived macrophages, and in CD14+ monocytes after BCG Mycobacterium 
challenge. Homeodomain interacting protein kinase 4 (HIPK4) is almost exclusively 
expressed in the testes (FANTOM5, GTEx Portal). Serta domain-containing 3 (SERTAD3) 
can, according to FANTOM5, be up-regulated in the breast cancer cell line MCF7. Periaxin 
(PRX) has, according to FANTOM5, two main TSSs and is mainly expressed in the eye, 
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neuronal tissue, lung, mesenchymal stem cells, and muscle. According to the GTEx Portal, 
PRX is expressed in the tibial nerve and in lung, and PRX protein expression is found in 
kidney and in the peripheral nerves, according to the Human Protein Atlas. PLD3 and 
SERTAD1 expression is activated by upper respiratory tract pathogens, which makes them 
interesting candidate genes for OM.  
The risk locus on chromosome 19 is frequently amplified in high-grade mucous ovarian 
cancer, suggesting that a gene or genes in this region contribute to cell proliferation and 
tumor growth in this malignancy [197]. This malignancy is thought to arise from cells of the 
peritoneal mucosa, a cell type that has some resemblance to epithelial cells of the middle ear 
mucosa. Thus, one may postulate that a gene or genes in this region contribute to the middle 
ear epithelial hyperplasia observed in COME, which could explain the genetic link of this 
locus to the pathogenesis of COME. 
We found a strong and genome-wide significant association between the risk locus on 
chromosome 19 and COME in the Finnish children. It was therefore quite intriguing that we 
found a highly significant association between this locus and COME in the UK cohort, but 
the association was in the opposite direction: the allele that conferred risk in the Finnish 
cohort conferred protection in the UK cohort. For many other common complex traits, GWA 
studies have revealed the same variants contributing to risk in all Caucasian populations 
[70]. It is possible that our initial finding is spurious, although the power for the study to 
detect a genome-wide significant variant with an allele frequency of 0.2 is 83%. One reason 
for a false result could be that we did not correct for multiple testing for the three different 
phenotypes: all affected, RAOM, and COME. However, these kind of contradictory results 
are not unusual in genetic studies; for example, opposite risk alleles of CC16 and CD14 genes 
have been found in allergy patients from Finnish Karelia, compared to allergy patients from 
Russian Karelia [198], and opposite risk alleles of the SLC15A1 gene have been found in 
Finnish vs. Swedish patients with inflammatory bowel disease [199]. 
There may be additional explanations that lead to such puzzling and contradictory findings. 
Concerning our findings of the risk locus on chromosome 19 and the opposing risk alleles of 
COME in the Finnish vs. UK children, one explanation may involve differences in the 
environments in the Finnish vs. the UK cohorts that may lead to differences in the 
pathogenesis of COME. Of note, despite the definition of COME in the Finnish and UK 
children being the same, the presence of long lasting MEE, there may be differences in the 
pathogenesis leading to the effusion in the different cohorts. It is well documented that the 
pathogenesis of COME is heterogeneous. In children who suffer from atopic rhinitis, the 
MEE has characteristics of Th2-type immune inflammation, while the MEE of children 
without atopic rhinitis has characteristics of Th1-type immune inflammation, as measured 
by the levels of eosinophil cationic protein, myeloperoxidase, and tryptase [200, 201]. Thus, 
in different cohorts with different environments there may be differences in the pathogenesis 
of COME. COME associated with atopic rhinitis has been reported in Denmark [202] as well 
as the UK [203], whereas in other cohorts, COME seems not to be accompanied by allergic 
rhinitis, including a separate cohort from the UK [204] and in a cohort from Finland [205]. 
Thus, the contradictory finding of opposing risk alleles in the Finnish vs. UK children may 
include differences in the pathogenesis of COME in the different cohorts. In some cohorts, 
the pathogenesis of COME may frequently involve Th1-type immune responses, whereas in 
other cohorts the pathogenesis of COME may be mainly driven by the opposing Th2-type 
immune responses.  
Concerning the hypothesis that differences in the Th1- vs. Th2-type immune response-
driven pathogenesis may result in opposing risk alleles in the Finnish vs. the UK cohorts, it 
is of note that the genes PLD3 and SERTAD1, which are located within the chromosome 19 
risk locus, have been implicated in the regulation of Th1- vs. Th2-type immune responses. 
In a systemic study of all transcribed genes in flow cytometry-sorted dendritic cell (DC) 
subpopulations, it was found that PLD3 was specifically up-regulated in the CD11b-positive 
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DC subpopulation, whereas SERTAD1 was specifically up-regulated in the CD8-positive DC 
subpopulation. CD11b DCs are thought to be dominant in Th2 immunity, while CD8 DCs 
dominate in Th1 immunity [206]. The CD11b- and CD8-positive DC subpopulations are 
crucial in the regulation of the balance between Th-1 vs. Th2-type immune responses. Th1 
and Th2 immune responses are complex, but, in a simplified model, the Th2 immune 
response is more proallergic, whereas intracellular pathogens, such as influenza virus and 
mycobacteria, elicit Th1 immune responses [207, 208]. Thus, the locus identified by our 
GWA study has potentially quite important functions in determining the fate of Th1- vs. Th2-
type immune responses. Therefore, the opposing alleles of the risk locus on chromosome 19 
may potentially amplify Th1-type middle ear inflammation in certain environments, but 
Th2-type middle ear inflammation in other environments. This would further explain the 
hypothesis that differences in the Th1- vs. Th2-type response-driven pathogenesis may result 
in the opposing risk alleles finding on chromosome 19 in the Finnish vs. UK cohorts. 
We have found a significant genetic association for OM on chromosome 19, the first genome-
wide significant finding for OM, in a subgroup of 509 patients with COME. The precise 
function of the locus remains unclear, and further fine-mapping of the locus should be done 
in order understand its role in the pathogenesis of OM.  
6.4. Strengths and limitations 
Genetic studies in the Finnish population possess an advantage due to its relatively 
homogenous population, although there are clear differences between different parts of the 
country. Isolates have developed over the course of time, enriching some genetic variations 
while others have become less common [209]. Our study cohort was a relatively 
heterogeneous Finnish dataset since it was gathered from the Helsinki area, where vast 
migration from others parts of Finland has taken place over the past 100 years. Despite this, 
from a global perspective, our study population was rather homogenous, which increases the 
sensitivity of the GWA study.  
In addition, the environments of our study children seemed to be quite similar. The two 
Finnish cohorts had been recruited in a similar way, they were predominantly not 
pneumococcal vaccinated, and had similar risk factors. Results from the two cohorts agreed 
very well, which proves the robustness of our results. 
Appropriate controls are essential for good genetic studies. Our control group included 
healthy blood donors and randomly selected volunteer individuals from different parts of 
Finland; all of the controls were Finns. Although they originated from different parts of 
Finland, the genetic background of the controls reflected those of the study patients, who 
were from the Helsinki metropolitan area, quite well. We had no information about the OM 
history of controls, however, and therefore were not able to exclude those controls with a 
history of OM, which may have somewhat reduced the sensitivity of our analysis. 
Additionally, genotyping the cases and controls on different arrays in the GWA study could 
potentially confer a source for error, but the Q-Q plots and genomic inflation factor λ did not 
reveal any discordance in our study.  
We recognize that there is a recall bias in our study setting due to collecting patient history 
via questionnaires. The study would have benefited more from collecting the patient data 
from patient medical records [210]. Another improvement to the clinical data would have 
been a prospective setting with a clinical examination of the patients, including 
otomicroscopy, audiograms and tympanometry. However, this was not feasible due to the 
large sample size. We did compare the data from the questionnaires with patient medical 
records in a sample (N=100) of our cohort; results showed that questionnaire responses 
were largely accurate (92-96%), similar to what has been demonstrated in other 
questionnaire-based studies [211]. The study would also have benefited from a larger cohort 
in order to increase power and decrease the risk for Type I error. Doubling the number of 
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cases in the GWA study would have increased the power from 62% to 97% to find variants 
with an allele frequency of 0.15.  
In all studies concerning a disease, the definition of the disease in question is of crucial 
importance. In our questionnaire, COME (glue-ear) was defined as MEE for more than two 
months. We recognize that many studies consider MEE for more than three months as 
COME, although two months has also been used [18, 212]. After an episode of AOM, MEE is 
detected in up to 23% of patients after 60 days [213]. Thus, our definition of COME may have 
been too broad. A stricter definition may have increased the sensitivity of the analysis.  
There are several reasons for the results of genetic studies to vary between cohorts and 
populations, especially in heterogeneous and complex phenotypes like OM. The cause for 
this may be related to both differences in the genetic backgrounds of the study cohorts as 
well as in the environments. The frequencies of polymorphisms vary, and distinct genetic 
variants could be risk factors in different populations. The diagnostic criteria are not always 
similar in the studies, which may affect the outcome. Vaccination strategies, daycare 
practices, parental smoking, breastfeeding, climate, and use of pacifiers differ across 
populations and cohorts. These factors all affect the prevalence of OM. As in other complex 
diseases defined by clinical signs, such as hypertension or osteoporosis, the pathogenesis of 
a disease can be quite heterogeneous even though it leads to the same phenotype. The same 
is also true for childhood RAOM and COME which can arise via different pathogenic 
mechanisms. All of these factors may contribute to differences in genetic studies in different 
cohorts, which is major challenge to future studies of the genetics of childhood OM. 
6.5. Future prospects 
Over the last 20 years, genetic research on complex diseases, like OM, has evolved, new tools 
have become available, and the amount of data and research papers have increased 
exponentially. Sample sizes for studies have grown, in order to be able to find risk variants 
with lower odds ratios and lower allele frequencies. To date, not many genetic variants 
conferring OM risk have been verified. Reasons for this include small cohorts and 
inadequately defined phenotypes. Results for the risk loci in A2ML1 [151] and FBXO11 [137] 
are the most solid. Our findings in the TLR4 region add to the strength of previous findings 
at that locus [113]. Our findings on genetic risk variants for OM in the TLR4 region and on 
chromosome 19 are small, but important pieces of a large puzzle explaining the genetic risk 
for OM. Much still remains unknown, and further studies are needed. As in many other 
CGDs, the genetic risk for OM is polygenic, consisting of both common and rare variants, 
some with low risk (like TLR4) and others with high risk (like A2ML1). It is likely that there 
is vast genetic heterogeneity between individuals, and populations. In order to find the 
variants, future studies will need larger cohorts, with well-defined phenotypes, from 
different populations around the world. Studies on gene-gene interaction are also needed, 
as well as studies on the biological function of the risk variants. Finding risk loci, and 
understanding their mechanism in the development of OM, could help in better 
understanding OM pathogenesis, determining high risk patients, and could possibly 
improve prevention and treatment.  
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7. Conclusions 
Childhood OM is heterogeneous, comprising several different phenotypes, with genetic 
background as an important risk factor. The genetic background of OM is also complex, 
probably with both common risk variants of low effect size and rare variants of high risk 
effect. Even though quite a few genetic studies on OM have been conducted, the results in 
different cohorts and populations are surprisingly different and much about this common 
disease is still poorly understood. Based on the studies presented in this thesis, the following 
conclusions can be drawn: 
1) Estimations from the first heritability study on OM in Finland show that, as 
has been seen in other populations, genetic background also contributes to 
the risk of childhood OM in the Finnish population.  
2) TLR4 variants are significantly associated with the risk of OM in Finnish children. 
The association is stronger in those with a more severe phenotype, namely in 
children with an onset of OM at a very young age and in those who undergo repeated 
insertions of tympanostomy tubes.  
3) A novel genetic locus on chromosome 19q is associated with a risk of OM, especially 
COME, in the Finnish population. However, the opposite allele conferred risk in the 
UK population, which may reflect differences in environmental factors that lead to 
differences in pathogenesis. The actual risk variant is unclear and the region should 
be studied further in order to find the underlying gene, and the mechanism by which 
it affects OM risk. 
4) The revealed genetic risk factors in the present studies are significant, but of low 
effect, only accounting for a fraction of the genetic risk for OM. Future genetic 
studies on childhood OM are needed in order to fully explain the genetic risk of the 
disease. 
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